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ABSTRACT
BACKGROUND:
Human Papillomavirus (HPV) is the most common sexually transmitted agent. These
small DNA viruses target the basal cells of the epithelium. While the HPV family is comprised
of more than 100 genotypes, only about 40 or so types are associated with human anogenital
infections. Infections with oncogenic HPV (probably high-risk 26,53,66,6 8,73,82 and high-risk
HPV types 16,18,31,33,35,39,45 ,51,52,56,58,59) are causally linked to the development of
cervical cancer (HPVI6 & 18 are related to about 99% of cervical malignanc y) as well as a
proportion of anal, oroph aryngeal, vulvar , vaginal and penile cancers and their associated
precancerous lesions. HPV is also the cause of genital warts (low-ri sk HPV types
06,11,34,40,4 2,44,53, & others). However, in most people HPV infection is transient and does
not lead to disease. Immune suppression increases the likelihood of HPV-related diseases, and
people with human immunodeficiency virus (HlV) infection or with HIV-positive partners are at
a higher risk of pre-canc er lesions and cancers, as well as genital warts. The literature suggests
HIV-HPV co-infection in women increases the risk of anal carcinoma by 30 times and the risk of
HPV assoc iated anal cancer is 163-fold greater in young men with HIV. A number of studies
have recommended that all HIV-infected individuals be rout inely screened for HPV-related
disorders to facilitate early detection and treatment because of the heightened risk of persistent
HPV infection with the risk of malignant transformation.
OBJECTIVES:
Primary: To determine the prevalence and distribution of high risk (HR) oncogenic HPV-types
in HIV-positive adults in Atlantic Canada.
Secondary: To correlate the prevalence of HR HPV genotyp es with underlying pre-malignant
lesions and maligna ncy through a cross- sectiona l study.
To corre late pre-ma lignant lesions and malignancy with patient s' demographics and underlying
risk factors.
This thesis is part of a larger prospective cohort study designed to follow consenting
persons with Hl'V infection in Atlantic Canada over a 3-year period subsequent to baseline
screening in year one. The data in this thesis are limited to that obtained at baseline in all four
Atlantic Provinces during the first year of the study. All Hlv-positive adults treated through the
participating infectious disease clinics were approached by the clinic physicians or nurses to
request participation in the study. Atlantic Canada has approximately 800 routinely followed
HlV-positive adults and we expected to enroll approximately 400 of them. This study was
approved by ethic committees of all participating institutions as well as the Public Health
Agency of Canada, the funding agency for the study.
Recruitment commenced in June, 2009. All procedures were performed after obtaining
informed consent. Consenting participants were required to complete a confidential
questionnaire to obtain demographic and risk factor data. Participants' identifiers were retained
to permit questionnaire data to be correlated with HPV related disease outcomes. SurePath
(Becton Dickinson) liquid cytology medium was used in the collection of oropharyngeal and
anal swab specimens from all males and females, and an additional cervical specimen was
obtained from females. All specimens were tested for cytologic abnormalities , HPV DNA and
genotyping . The study cohort will be followed up with the above protocol for a period of 3 years.
These results will be subsequently used to assess any HPV related disease outcome and
genotypic specific information. Consent also gives access to patients' medical files for
information on viral load, CD4+T cell count and treatment regimens in order to correlate these
factors with disease outcome.
The study analysis is based on a total of 300 patients; of these 91.7% were males. The
population and gender distribution among the provinces were: Nova Scotia, Halifax (NSH) -
total 150 patients, of these 142 (94.7%) were males; New Brunswick, Moncton (NBM) - total 90
patients, of these 85 (94.4%) were males; Newfoundland and Labrador, St. John's (NLSJ) - total
44 patients, of these 34 (77.3%) were males; and New Brunswick, Saint John (NBSJ) - total 16
patients, of these 14 (87.4%) were males.
iii
The mean (SO) age of the study population was 46.9 (9.36) years and its distribution by age
categories was: 62 (20.7%) aged 25 to 39 years; 209 (69.7%) aged 40 to 59 years; and 29 (9.6%)
aged 60 years and older.
There was no significant difference in the association of cytologic results with C04 cells
count and plasma viral load levels.
A total of232 (77.3%) of the participants tested positive for any HPV infection with 125
(54.0%) showing multiple HPV types . Up to 46 HPV genotypes were detected, of which 39%
were HR oncogenic types and 61% of low-risk (LR) types . The most frequently detected HR
HPV types among all specimens were: HPVI6 11.8%; HPV52 7.2%; HPV45 5.6%; HPV51
5.4% & HPVI8/HPV59 4.6% each. Six HR HPV types: 16 (p<O.OOI); 45 (p=0.044); 51
(p=0.014); 52 (p<O.OOI); 53 (p=0.045); and 59 (p=0.006) were more frequently associated with
anal lesions; from them atypical squamous cells of undetermined significance (ASC-US) were
detected in 37 (12.3%) patients; atypical squamous cells of undetermined significance cannot
exclude high-grade intraepithelial lesion (ASC-H) in 3 (0.5%) patients ; low-grade squamous
intraepithelial lesions (LSILs) were detected in 35 (11.6%) participants ; and high-grade
intraepitheliallesions (HSILs) in 3 (0.5%) of them. HPV51 was detected in one oropharyngeal
specimen with ASC-US cytologic changes ; and HPV35 was more frequently associated with
cervical lesions (ASC-US in one female ; LSIL in one patients also; and LSIL cannot exclude
high-grade lesion (LSIL/HSIL) in one female participant). The highest number of cytologic
abnormalities was reported in anal specimens (26%) as compared to cervical and oropharyngeal
specimens (12% & 0.3%, respectively). Cytologic changes were significantly associated with
patients' high risk behaviour such as unprotected anal and vaginal sex. All patients with detected
lesions were referred to an appropriate specialist for further investigation.
The overall prevalence rate of the cases with the high-risk (HR) HPV genotypes was
46.6% (108/232). The overall prevalence of the cytologic abnormalities caused by HR HPV
types in the study population was 27.3% (82/300) during the screening year.
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CONCLUSION:
In this study, 74% of 300 patients studied had normal anal cytology, with 26% having
abnormal anal cytology, and with 15.3% (46/300) of patients having unsatisfactory anal
specimens for evaluation. Abnormal cytology was reported mostly as ASC-US (12.3%) and
LSIL (11.7%), with fewer samples showing HSIL (1.0%). All participants with detected anal,
cervical and oropharyngeal precancerous lesions were referred to specialists to undergo a high-
resolution anoscopy (HRA) and colposcopy with biopsy (the results of these tests will be
analyzed as a part of the larger study). The results of the data presented here are comparable with
the results from other studies. Follow-up analysis of anal, cervical and oropharyngeal biopsy
results are required to draw conclusions about real prevalence of cytologic abnormalities in the
study population; cytologic outcomes have to be correlated with histologic outcomes.
KEYWORDS:
Human papillomavirus infection, anal cancer, cervical cancer, head and neck cancer,
HPV genotyping , HPV prevalence and incidence, HPV and malignancy, HPV risk factors, HIV-
HPV co-infection .
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1.1 Introduction to the Thesis
Human Papillomavirus (HPV) infection is estimated to be one of the most common
sexually transmitted infections (STI) in Canada and around the world.
The Centre for Disease Control (CDC) estimates that at least half of all sexually active
individu als will acquire HPV at some point in their lives (CDC Fact Sheet , 2009) but this viral
infection usually clears up by itself and causes no signs or symptoms .
The greatest risk factors for infection with HPV in the general population are gender ,
young age and sexual activity. Besides these factors, common risk factors for HPV infection and
clinical sequelae of infection include high number of sexual partners and co-infection with
Chlamydia trachomatis or Herpes Simplex Virus (HSV). Most HPV infections arc non
consequential, being cleared by the immune system and do not results in clinical complications.
While HPV infection is mostly transient in the majority of individuals and does not lead
to disease , immune suppression increases significantly HPV related diseases and those with
human immunodeficiency viral (HIV) infection or with HIV-positive partners are at a higher risk
of pre-cancer lesions and cancers as well as genital warts (Kreuter A. and Wieland U., 2009) .
Furthermore , for those who have HIV infection , there is a heightened risk of rarer and/or more
aggressive forms of cancer which tend to be more advanced , occurring in younger age with
poorer prognosis and are more likely to spread to unusual sites (Jensen et aI., 2007; Lillo &
Uberti-Foppa , 2006; Nicol et aI., 2005; Palefsky et aI., 1999; Schlecht et aI., 2005 ; Sebitoane ,
2005) .
The risk of HPV associated malignancies is genotype-dependent. However, from the
standpoint of HPV epidemiology, there is a paucity of informati on on HPV genotype distribution
and the risk of anal, oropharyn geal and cervical cancer among those living with HIV in Canada.
This is a prospective cohort study involving HIV-positive persons (PHAs) treated at the
Infectious Diseases clinics in Canada's four Atlantic Provinces: Newfoundland and Labrador
(NL), New Brunswick (NB), Nova Scotia (NS), and Prince Edward Island (PEl). While the HPV
prevalence is likely to be quite high in the target population , testing for the high risk (HR) HPV
genotypes and associated cytologic abnormalities should identify those at increased risk of
malignancy . Moreover , determining the HPV genotype will be beneficial in assessing the relative
risk of earlier developing malignanc y and will also be quite useful as part of ongoin g patient
management.
1.2 Epidemiology ofHIV-HPV Co-Infection
Transmission of HPV infection occurs primaril y by skin-to-skin sexual contact and HPV is
prevalent in all sexually active population s. Epidemiologic studies clearly indicate that the risk of
contracting HPV infection in the general population is influenced by: sexual activity itself;
sexual activity at an early age; multiple sexual partners at any time of life or being the partner of
someone had multiple sexual partners; personal history of other sexually transmitted diseases.
The primary immune response to HPV infection is cell-mediated; therefore , conditions that
impair cell-mediated immunit y such as human immunodeficiency viral disease should increase
the risk of acquisition and progression ofHPV.lnfection with HIV is an additional risk factor for
developing anal cancer , with relative risks (RR) for men seropositive for HIV of about 60 for in
situ anal cancers and about 40 for invasive anal cancers (Frisch et al., 2000) compared to HIV-
seronegative men.
It also was reported that , compared to men who have sex with men seronegative for HIV,
those who are seropositive have a 2-fold higher risk of anal cancer (Goedert et aI., 1998).
Furthermore, the incidence of anal cancer in seropositive for HIV men has increased
significantly since the introduction of highly active antiretroviral therapies (HAART) (Bower et
aI., 2006 ; Hessol et aI., 2007 ; D'Souza et aI., 2008 ; Pikett y et aI., 2008). Lampinen et al. in 2006
reported that the increased risk of anal cancer among HIV-positive men who have sex with men
(MSM) , can be as high as 140-fold compared to HIV-positive men who are not practicing sex
with men. The risk of HPV associated anal cancer is 163-fold greater in young men with Hl'V
than in young HIV-negative men (Breese P. et aI, 1994). Therefore , the progression of atypical
squamous intraepithelial lesion (ASIL) to invasive anal cancer is influenced by a number of
factors including: HIV seropositivity, infection with multiple HPV serotypes and a high level of
DNA of high-ri sk serotypes (Uronis & Bendel! , 2007).
Uterine cervical cancer is by far the most frequently recognized HPV-associated cancer , with
an association with HPV 16 and HPV 18 (Clifford et aI., 2003 ; Pretet et aI., 2008) . Many studies
have shown that HIV positivity is associated with an increased prevalence of cervical HPV
infection and CIN (Palefsky J, 2006). Women with HIV or in a relationship with HIV-positive
individuals are at increased risk for anal and cervical cancer as weI! as genital warts . In women
who are HIV-HPV co-infected, lesions tend to be high grade with a shortened interval between
infection and invasive cancer (Apgar BS and Brotzman G, 1999). HIV-HPV co-infection is
thought to increase the risk of anal carcinoma by 30 times (Sobhani et aI, 2004) and these women
have a 6.8-fold greater risk of invasive anal cancer when compared with HIV-negative women
(The National Cancer Institute Women 's Health Report , 2007).
HPVI 6 is found in an even higher proportion of anal cancers than cervical cancers (Fox P,
2006). Likewise, anal cancer may be preceded by a series of precanc erous lesions, known as anal
intraepithelial neoplasia (AIN). The incidence of anal cancer is elevated in HIV-negative men
who have sex with men (MSM) and is even higher among HIV-positive MSM (Chin-Hong PV &
Palefsky JM, 2005).
A recent review conducted by the International Agency for Research on Cancer (IARC)
concluded that while cervical cancer is virtually entirely (99%) related to HPV, other sexually
transmitted cancers are associated with HPV to a varying extent: penis 40%, anus 90%,
vulva/vagina 40% and oropharyn x 12% (Munoz N. et al, 2006). The current estimated
worldwide burden of cancer cases caused by HPV and by HPV types 16/18 is 5.2% and 3.7%,
respectively (Parkin OM, 2006).
As a result of this evidence, a number of studies have recommended that all HIV-infected
individuals should be screened for HPV-related disease for early detection and treatment given
the heightened risk of persistent HPV infection , malignant transformation, widespread disease
and frequent recurrenc es (Palefsky JM, 2005).
1.3 Laboratory Definition of HPV infection
Human Papillomavirus (HPV) is a virus that can lead to abnormal tissue growth (warts) and
result in changes to the affected cells. Persistent infection with certain types of HPV can lead to
cervical cancer, as well as anal, vaginal , vulvar , penile and oropharyngeal cancers (National
Cancer Institute (NCI) Dictiona ry, http://nci .nih.gov/dictionary 0 .
The HPV family is ubiquitou s in the human population and more than 100 virus types have
been identified (de Villier s et aI., 1997). The viruses are small double-stranded DNA viruses
with a genome of approximat ely 8kb that specifically target the basal cells of the epithelial
mucosa (zur Hansen & de Villiers, 1994) and the metaplastic cells at the squamocolumnar
jun ctions of the cervix and anus. Additionally, HPV may infect the glandular epithelium of the
endocervix, resulting in neoplasms, such as adenocarcin oma in situ or invasive carcinoma.
Low-risk HPV types (6,11,34,40,42,44,53,54,55,57,61,70,71,72,81,84) are associated with
benign lesions such as warts, while infections with probably high-risk (26,53,66 ,68,73,82) and
high-risk HPV types (16,18,31,33,35,39,45,51,52,56,58,59) have the potenti al to progress into
malignant lesions.
1.4 Natural History and Pathogenesis of HPV infection
The overwhelming majority of ano-genital cancer patients show serological,
histopathological or molecular evidence of prior infection with HPV, and viral DNA sequences
can be detected in tumor tissue. The tumors and cell-lines derived from them continu e to express
the viral E6 and E7 HPV proteins, suggesting that these two proteins are required for the
continued growth of the cells (Schwarz et aI., 1985; Smotkin and Wettstein, 1986; Androphy et
al., 1987; Banks et al., 1987). The "E" designation indicates that these two primary oncogenes
are expressed early in the HPV life cycle.
The products of these two genes alter the host-cell metaboli sm to favor neoplastic
development. Wemess et al (1990) showed that the E6 proteins from HPVI 6 and HPVI8 are
capable to bind to p53 protein of the host-cells, this binding promotes the degradation of p53 via
the ubiquit in pathway (Scheffner et aI., 1990 & 1993).
Subsequent work has shown that the Eo-mediated degradation of p53 is dependent upon a
cellular protein, E6-associa ted protein - E6-AP (Huibregtse et aI., 1991 & 1993). An effect of
this targeted degradation is to prevent apoptosis of the infected host epithelial cells. The host-
cells telomerase is also activated, further augmenting oncogenic changes. A natural consequence
of the E6-induced degradation of p53 is the inhibition of both p53 growth arrest and apoptotic
functions of the normal cell cycle . Once squamous and squamoco lumnar tumor cells metastasize,
mutations within p53 become more frequent (Croo k & Vousden, 1992). This seems to indicate
that the presence of mutant p53 gives cells a competitive advantage over cells in which p53
activity is not abrogated by E6 proteins. This supports the idea that mutants of p53 can have a
domi nant-negative phenotype.
In order to have a producti ve infection, HPV types must infect keratinocytes in the basal
layers of the epidermis. HPV undergoes vegetative replication only in differentiating epithelium
and the virus requires cellular DNA replication proteins in order to replicate its own DNA.
The low- and high-risk HPVs differ in their sites of DNA replication within the
different iating epithelium (Doorbar et aI., 1997). The low-risk HPV types generally replicate
only in the lower levels of the stratified epithelium where the keratinocytes are still undergoing
normal cell division. In contrast, the high-risk HPVs replicate their genomes in the higher levels
of the epithelium where the keratinocytes would have normally entered the process of terminal
differentiation and switched off DNA replication. Thus, the high-risk HPV types stimulate cells
to replicate DNA in a more unnatura l environment than the low-risk HPVs. High-risk HPV types
also interfere with cell cycle regulation via the E7 proteins by modulation of the induction of
DNA synthesis (Sato et aI., 1989; Banks et aI., 1990).
The E7 protein has a similar effect on host-cell metabolism by binding to retinoblastoma
protein and inhibiting its function (Scheffner M, et aI1993). Both E6 and E7 proteins may cause
chromosomal destabilization, and inhibit cyclin-dependent kinase inhibitors and host interferons
(Shindoh M, et al 1995).
The integration of HPV DNA into the host DNA leads to an increase in cellular proliferation
and the likelihood of malignant transformation (Stanley M, 2003).
1.5 Tumorigenic Potential of HPV
Human Papillomavirus (HPV) is a significant source of morbidity and mortality worldwide.
Currently there are no effective treatments for individuals with genital warts or malignant
lesions; management entails removal of discrete lesions and monitoring for recurrences.
Prophylactic vaccines have become available and hold promise to significantly reduce the burden
(morbidity and mortality) associated with HPV infections. A bivalent vaccine (Cervarix) has
been formulated to protect against the two most common high-risk HPV types for cervical
cancer, 16 and 18, and the second quadrivalent vaccine (Gardasil) targeting HPV 16 and 18, and
the two most common low-risk types, HPV 6 and 11 has recently become available. The
vaccines contain papillomavirus-like particles (empty shells of viral structural proteins) that
produce a neutralizing antibody response, which is believed to prevent papillomavirus from
infecting host cells (16). The Society of Obstetricians and Gynecologists of Canada estimates
that 10% to 30% of the Canadian adult population is infected with HPV. This is in line with
research from the US and Europe which has shown that 10% to 40% of sexually active women
are infected by HPV at anyone time (http://www.hpvinfo.ca/health-care-professionals/what-is-
hpv/incidence-and-prevalence-of-hpv-in-canadaD. There are approximately 6.2 million new
HPV infections occur every year in the United States, and approximately 20 million individuals
are currently infected
(Centers for Disease Control and Prevention , Genital HPV Infection: CDC Fact Sheet, CDCP
2004).
Almost all cases of invasive cancers of the cervix, most other ano-genital tract cancers, and
approximately 20-25% of head and neck cancers contain oncogenic HPV viruses (Predominantly
types 16, 18, 31, and 45 for cervical and other ano-genital tract cancers, and type 16 for
oropharyngea l cancers) (Zur Hausen, 1996; Munos et al., 2003).
In the ongoing Study to Understand the Natural History of HIV/A IDS (SUN) in HlV-p ositive
adults by Vellozzi C et al in 2009, the prevalence of HPV in the cervix and anus was 86% and
93% respectively, and for high risk HPV types the prevalence rates were 68% and 85%,
respectively. A history of anal sex was not predictive of an abnormal anal cyto logy. These
results, although not completely independent of a history of anal intercourse, are explained by
the anatomical proximity of the anus and the genital tract. HPV exposure of either anatomical
site can result in tracking and infection of the other site.
1.5.1 HNSCC (Head & Neck Squamous Cell Carcinoma)
The involvement of HPV in oral and oropharyngeal carcinogenesis was first proposed in
1983 by Syrianen et al. Several studies have reported HPV DNA in normal, pre- and malignant
oral mucosa although many of them were small hospital-based cross-sectional studies (Hodge et
al., 1985; Hoshikawa et al., 1990; Blot et al., 1994). More recently, larger studies of HPV DNA
prevalence in the head and neck mucosa have shown that HPV may be an additional independent
risk factor for a subset of HNSCC (Schwartz et al., 1998; Smith et al., 1998, 2004; Herrero et al.,
2003; Hansson et al., 2005). Other studies suggest that despite the majority of cases of oral and
oropharynge al cancer being attributed to tobacco and alcohol usage; there may be differences
between the tumors that develop in smokers/drinkers and those that develop in non-smokers/non-
drinkers (Koch et al., 1999; Wiseman et al., 2003).
A meta-analysis of cases from 1982 to 1997, examining the risk ofHPV detection in normal,
pre-, and cancerous oral tissue, showed that the probability of HPV being detected in mucosa
increased with increasing degree of dysplasia (Miller and Johnstone, 2001).
In a total of 4680 samples from 94 studies, these investigators reported that the pooled
probability of detecting HPV in normal mucosa was 10% (95%CI=6.1-14.6), in benign
leukoplakia was 22% (95%CI=15.7-29.9), in intra-epithelial neoplasia 26.2% (95%CI=19.6-
33.6%), in verrucous carcinoma 29.5% (95%CI=23.0-36.8), and, finally, in oral squamous cell
carcinoma 46.5% (95%CI=37.6-55.5). HPV 16 and 18 were detected in 30% of oral squamous
cell carcinomas (OSCC), while other high-risk HPV genotypes were detected in less than 1% of
head and neck tumors. There was substantial heterogeneity in detection rates between studies
which may be attributed to several factors, including: variations in prevalence between
geographic locations of the studies, and between head and neck anatomical sides (Kreimer et aI.,
2005); multiple HPV detection methods (polymerase chain-reaction [PCR], in situ hybridization
[ISH], and others).
Two large studies have recently strengthened the correlation between HPV-associated ano-
genital cancers and HNSCC. The first study (Frisch and Biggar, 1999) was designed to
determine whether there was a risk of tonsillar or other HNSCCs among patients with HPV-
associated ano-genital cancers. The risk of tonsillar cancer (RR=4.3, 95%CI=2.7-6.7) or other
HNSCCs (RR=2.3, 95%CI=1.7-3.0) was increased. Patients with cancers unrelated to HPV had a
relative risk (RR) closed to 1. The second study (Hemminki et aI., 2000) investigated the
occurrence of second primary cancers in the upper aero-digestive tract among 135,386 women
(Sweden Family Cancer Database) who were initially diagnosed with cervical or in situ cervical
carcinoma, as well as the occurrence of first primary cancers among their husbands was assessed.
The overall standard incidence ratios (SIR) for females with carcinoma in situ was 1.86 with
the highest SIR attributed to the larynx; and for females with invasive cervical cancer , the overall
SIR was 2.45 with the highest SIR attributed to the hypopharynx. Husbands of women with
carcinoma in situ and with invasive cervical cancers had an overall SIRs of 1.43 and 1.37,
respectively with the highest SIR attributed to the tonsils .
Evidence supports the idea that HNSCC is a multifactorial disease with at least two
pathways , one driven by smoking and alcohol consumption , with another driven by HPV.
Although these pathways are possibly distinct , HPV infection and smoking are not mutually
exclusive (Braakhuis et a!., 2004; Ragin et a!., 2004 ; Ferris et a!., 2005).
1.5.2 Anal Cancer and HIV
Anal cancer is very similar to cervical cancer biologically , including a causative association
with human papillomavirus (Hoots , Palefsky et a!., 2009) . Furthermore , within the anal canal the
squamocolumnar junction (TZ) is anatomically very similar to the squamocolumnar junction
(TZ) on the cervix ; at this junction there are typically areas of squamous metaplasia , as on the
cervix , which are especially susceptible to the oncogenic effects of HPV. It is in these areas the
basal cells are often closest to the surface which can facilitate infection by HPV. The equivalent
of high-grade CIN, high-grade anal intraepithelial neoplasia (HGAIN) . is known to progress to
anal cancer (Watson et al., 2006) . Several population-based studies showed that anal cancer rates
have been increasing , and that the trend has been particularly dominant in urban populations,
particularly those centres with high concentrations of homosexual males or men who have sex
with men (MSM). Increasing rates have been reported in Copenhagen (Frisch M, et al 2003),
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London (Newsom-Davis T & Bower M, 2010) and San Francisco (Cress RD & Holly EA, 2003 ;
Palefsky 1M et al, 2005) ; the highest increase in anal cancer was reported in San Francisco , with
rates in men aged 40 to 64 years increasing from 3.7 to 20.6 per 100,000 from 1996 to 1999
(Chris RD & Holly EA, 2003) .
The incidence of HPV-associated anal cancer is high among HIV-positive men who have sex
with men (MSM) , and possibly in I-lIV-positive women (Kreuter A. et aI., 2008). Highly active
antiretroviral therapy (HAART) was introduced for widespread use in 1996, and since then the
incidence of anal cancer has dramatically increased in the HIV-positive population now
exceeding the highest incidence of cervical cancer among women reported anywhere in the
world (Palefsky 1M. et al, 2005). Three recent studies have shown a high incidence of anal
cancer among HIV-positive MSM since 1996. One study was conducted by Piketty et al. and
showed an incidence of anal cancer from a registry in France of 75/100,000 person-years among
HIV-positive MSM since 1999 (French Hospital Database). Patel et al. showed an incidence of
78/100,000 person-years among HIV-positive MSM from a Surveillance , Epidemiology , and
End Results Program-HIV registry match in the United States since 2000. And, finally, D'Souza
et al. showed an incidence of 137/100,000 person-years among I-lIV-positive MSM since 1996
among men participating in the Multicenter AIDS Cohort Study. The prevalence of anal HPV
infection in MSM of all age groups is high (19.8%), and does not decrease with age in HIV-
negative men who remain sexually active with multiple sexual partners (Chin-Hong et al., 2004
The "EXPLORE" study). The data from this (EXPLORE) large cohort of MSM of all ages
suggest that individuals might be susceptible to reinfection, at least transiently, following re-
exposure , so that immunity to specific HPV types does not persist.
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It is considered that these men are repeatedly clearing and then becoming reinfected with HPV,
giving rise to low- and high-grade anal intraepithelial neoplasia (AIN) which in many cases is
transient. This fact would explain the absence of an age effect on the prevalence of AIN. The
absence of high-risk HPV at a single time point and from a single site cannot guarantee that the
virus is not present at another site or that the individual might not become infected at a later date
(Fox et aI., 2005). One problem here is the method of identifying the HPV may not always be
picking up the infection; perhaps individuals with HIV have a lower clinical threshold for
infection than do general population. If this is true, the method of HPV detection becomes
critical as the current assays include clinical thresholds which may not be applicable to this
population.
HIV-positive patients other than MSM can have AIN even where there has been no history of
receptive anal intercourse; but the risk for these other groups appears to be much lower (Wilkin
et aI., 2004). This study showed that 18% of men with no history of receptive anal intercourse
had AIN based on cytology, compared with 65% for those who practiced receptive anal
intercourse. The difference still remains significant based on histological findings, at 23%
compared with 52%. There is also an interpretive factor that needs to be accounted for in both
the histologic and cytologic interpretations .
It is also well established that the risk of both prevalent and incident high-grade AIN
increases as CD4 cell count falls (Kiviat et aI., 1993; Palefsky et aI., 1998).
Evidence suggests that, unlike most other malignancies occurring in the HIV-positive
population, anal cancer is potentially preventable, using methods similar to those used to prevent
cervical cancer in women (Palefsky J.M., 2009).
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1.5.3 Cervical Cancer
Cancer of the cervix (CC) is the second most common cancer among women worldwide with
an estimated 529,409 new cases and 274,883 deaths in 2008. About 86% of the cases,
representing 13% of female cancers, occur in developing countries . Worldwide, mortality rates
of CC are substantially lower than incidence with a ratio of mortality/incidence of 52% (IARC,
GLOBOCAN 2008). In the last few decades the incidence of cervical cancer has declined with
the introduction of cervical cytology screening to identify and treat women with cervical cancer
precursor lesions (high-grade CIN, or CIN 2-3, and particularly CIN 3). The treatment of high-
grade CIN through a variety of modalities has also substantially reduced the incidence of cervical
cancer. HPV is one of the most common infections of the female genital tract, and it is also one
of the most costly. HPV-associated health care costs include routine Pap tests, treatment of
genital warts, follow-up of cytological abnormalities , and management of cervical malignancies.
High-risk, oncogenic HPV types 16 and 18 are associated with 99.7% of all cervical cancers, as
well as cytologic abnormalities which carry significant health care costs and psychosocial
morbidity. There is now considerable evidence that HPVs that are primarily transmitted through
sexual contact are found in over 99% of the cases of invasive cervical cancer. Mougin C. et al in
200 I found that there was a long latency period between primary infection and cancer which led
the authors to suggest that additional risk factors are involved in the process of tumor
development. These risk factors may include (Bell MC. et al in 2011) younger age, lower
education, nutritional status, more sexual partners, younger age at first sexual experience and
first pregnancy, and more pregnancies (p<0.003). Also associated were recreational drug use,
current smoking and history of sexually transmitted diseases. So, although from 10% to 40% of
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women can be infected by HPV during their sexual life, only a small minority of them is at risk
for developing cancer.
The first population-based study to investigate the prevalence of HPV types in all grades of
cervical neoplasia as observed in a large sample of high-risk population was conducted by
Herrero R et al in 1999. As observed for HSILs, HPVI6 was the most common type (I 1.8%)
followed by HPV52 (5.6%) and HPV51 (5.4% of positive subjects). Each pre-cancerous lesion
tested had at least one high-risk HPV type; however most were associated with multiple HPV
types. In Canada, women account for 17.3% (I1,191 cases) of the 67,442 positive HIV test
results reported since November Ist, 1985, and represent a growing proportion of new HIV
diagnoses (26.2% in 2008 compared with 11.7% before 1999) (www.phac-aspc.gc.calaids
sidalpublication/Survreport/2008/dec/index-eng .php). Women who are HIV-positive are at
increased risk for human papillomavirus infection, cervical cancer, and precancerous lesions
compared with uninfected women (Saslow 0 et al. 2002; Chin KM et al. 1998; Massad LS et al.
1999; Maiman M et al. 1998; IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans Human Papillomaviruses, 2007). Canadian researcher Pamela Leece in her 2010
retrospective cohort study "Cervical Cancer screening among HIV-positive women" wrote: 33%
(42 of 126) of the HIV-positive women who underwent cervical screening had at least I
abnormal test. Abnormal results were not significantly related to viral load; however, there was a
significant relationship between lower recent CD4 cell count (<200 cells/ul, vs. ~200 cells/ul.)
and having I or more abnormal test result (OR=6.64, p=0.04). Rates of cervical screening in
HIV-positive women in Ontario are estimated to be 68.6% during a 3-year period, indicating that
HIV+ women might receive less screening than general population (Ontario Cervical Screening




2.1 Study Design and Study Centres
This thesis is part of a larger prospective cohort study which was designed for a screening
year followed by three consecutive years of observation and surveillance of the participant s.
Study centres are located in St. John's (NL), Saint John (NB), Moncton (NB) and Halifax (NS).
Patients from Prince Edward Island (PEl) are seen in Halifax and Moncton . The study poster
with the contact info was distributed at the local HIV clinics (Appendix A). The screening year
recruitment process started in June 2009 and is still ongoing. All HIV-positive patients seen
through the Newfoundland & Labrador (NL), New Brunswick (NB), Nova Scotia (NS) and
Prince Edward Island (PEl) participating Infectiou s Disease (10) clinics were approached by the
clinic physicians or nurses to request participation in the study. They explained the study to the
potential participants and obtained the written consent. Consent was obtained using ethics board
approved consent forms with the clear understanding that patients ' unique identification number s
(lOs) will be retained in order to conduct future patients follow-up s (Appendix B). The consent
was also obtained to access the patient's medical file information such as HIV viral load, CD4
cells count , and history of sexually transmitted infection s in order to correlate these factors with
disease outcome. All consenting participants were enrolled during a two-year period and will be
followed up at the scheduled intervals as per standard practice for up to three years . During
initial interviews , participants were administered a confidential patient' s questionnaire to obtain
demographic and risk factor data (Appendix C).
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At the time of enro lment the clinic physic ian/ nurse filled out the l 2-item cl inic ques tionnaire
with the earliest tests result s related to the HIV markers and pa tient health status (Appe ndix D).
They also filled out the patient' s enro lme nt card in order to register the dates of the speci men
co llection at baseline and during the three follow -ups (Appendix E). During the follow -up visits,
the 9-item cli nic questionn aire has to be obtained from the patient' s medi cal file with the latest
data for the yea r of observa tion.
2.2 Study Population
All HIV-positi ve adults 2: 18 years of age trea ted at the vario us researc h sites were invited to
partic ipate in the study. The exclusio n criter ia include only patient's unwill ingness to part icipate
in the study. Atlantic Ca nada has approx imate ly 800 HIV-pos itive cases and we expec ted to
enro ll app roxim ately half ofthem (400 part icipants). However, at the date of conducted ana lysis
for the screeni ng year of the study 300 pati ents had been enrolled. The rec rui tment process wi ll
be continued unt il the expec ted numb er of part icipants wi ll be reached.
2.3 Specimen Collection/Centralization of the Data
The labels for eac h study site as well as consent form s, enro lment ca rds and questionnaires
were designed and printed pr ior to the study begi nning. Each site has its particular label co lor:
New Brun swick-red labels, Newfo undland-blue and Nova Scotia-g reen labels. Each label
(patient's ID in the research) includ ed the site nam e, pat ient' s personal numb er, and the type of
speci mens co llected (A, 0 , C), e.g. NLS J 001 and checke d A & 0 squares on the label indicates
that this patient was a male (only ana l and orophary ngea l spec ime ns were obtained), his numb er
in the resea rch was 00 1 and he was from Newfo undland, S1. John's. In May 2009 the personal
resea rch kits were asse mbled and shipped out to each study centre .
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The personal kit for the screening year included: labeled paper-work (consent form, 21-
item patient's questionnaire, 12-item clinical questionnaire, and laboratory requisition form with
the enrolment card), Pap vials with liquid media, and packs with Dacron and cotton swabs (for
anal and oropharyngeal specimens, respectively), cervical brush, paper and plastic biohazard
bags.
In order to standardize collection among the study sites, the detailed guidelines for specimen
collection (NYS Guidelines recommendations on anal pap smears -Appendix F) were sent to the
research sites at the beginning of the screening year in June 2009. Trained personnel collected an
oropharyngeal and anal swab specimen from all consenting males and females, females were
asked to provide an additional cervical specimen. In our study we used Surel'ath" Liquid-Based
Pap test (BD Diagnostics) supplies for cytologic analysis: Surel'ath" vials with 10 ml of
ethanol-based media and blue cervical brushes with the detachable end
(http://www.bd.com/tripath/physiciansD were used for collection. The cervical transformation
zone (TZ) is the site of origin of most cervical neoplastic lesions, and, as in sampling for cervical
cytology, were targeted in the study for exfoliated cell collection. The standard technique was
used for obtaining anal cytology by rotating a water-moistened Dacron swab in the anal canal
without direct visualization (blind or non-guided method) above the squamocolumnar transition
zone (TZ), which is approximately 2 cm from the anal verge. (NYS Guidelines recommendations
on anal pap smears, NYS DOH AIDS Institute's HIV quality-related website -
http://hivguidelines .org/ContenLaspx). The oropharyngeal specimen was collected by using
sterile cotton swab from the back side of the patient's throat.
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The collection devices were then each placed in a SurePath collection vial. The sample
handling for all three specimens was similar. The resulting solution was stored at the room
temperature in the PHL and later used for the preparation of thin-layer slides for cytologic
analysis.
All specimens and completed paper-work were sent to the Public Health Laboratory (PHL),
St. John's. The specimens were shipped under conditions that protected sample integrity for
testing and, equally important, protected the safety of all who come in contact with the shipment
(WHO Guidance on regulations for the transport of infectious substances)
(http://www.who.int.csr/resourceslbiosafety/WHO I-ISE EPR 2008 lG/htrnl). In the PHL the
vial's content was divided in two parts and sent to different laboratories : the first one-third to the
Eastern Health Regional Cytology Laboratory, St John 's and the second two-thirds to the
National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) in
Winnipeg for HPV DNA testing and genotyping. The cytology test results were forwarded to the
study physicians through the lead principal investigator who coordinated the study logistics with
a secure database and, in collaboration with other study investigators, analyzed and prepared
reports to the PHAC in Ottawa. The detailed study Flow Chart is showed in the Appendix G.
2.4 Purpose of the Study
Atlantic Canada is currently poised to effectively establish an HIV-HPV surveillance
network. This capacity comes from the two Atlantic Canada initiatives: the Atlantic
Interdisciplinary Research Network (AIRN), formed in 2005, and the Atlantic Canada HIV
Education Network (ACHIVE), established in 2002.
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From the standpoint of the strength of the existing Atlantic Canada networks , it is a sound
prospect to establish an "Atlantic Canadian HIV-HPV Surveillance Network", which could
provide valuable information and potentially serve as a model to the rest of Canada.
The study data and results will also be quite useful and included as a part of ongoing HIV
patient care and management. It can potentially initiate some changes in primary care policie s
with follow-up recommendations for the annual screening of all HIV-infected adults , regardle ss
of age , to perform both a visual inspection of the perianal region and a digital rectal examination
with anal specimen collection for the cytology evaluation and HPV genotyping.
Further , determining HPV genotype prevalence will be beneficial in assessing the relative
risk (RR) of acquired malignancy and will provide useful information in the era of genotype-
specific HPV vaccination.
Finally, this study should contribute to the national data on genotype distribution and add to
the existing of the published knowledge on HIV-HPV co-infection.
2.5 Study Goals
The main goal of this study was to determine the prevalence of high risk (HR) oncogenic
HPV types in HIV-positive adults both males and females in Atlantic Canada and correlat e them
with underlying pre-malignant lesions and malignancy through cross-sectional study of the
screening year data .
The other goals of the study included:
• Correlation of the detected pre-malignant lesions and malignancy with patients'
demographics, behavioral risk factor s such as smoking, multiple sexual partners ,
unprotected sex, and their history of sexually transmitted infections .
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• Correlation of the detected pre-malignant lesions and malignancy with patients' HIV
markers and health status (base line CD4 cells count, viral load level, history of
anoge nital warts/ malig nancy) .
2.6 Researc h Questions
The primary resea rch question
What were the distributi on and prevalence of high-risk oncoge nic HPV genotypes in the HIV-
posit ive popul ation in Atlantic Canada?
The secondary research questions
Were the high-risk oncogenic HPV genotypes correl ated with underlying anal, oropharyngea l
and cervical pre-mal ignant lesions and malignancy?
Were the detected pre-malignant lesions and malignancy corre lated with patients' demographi cs
and behaviors as well as with pat ients' health status?
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CHAPTER 3
DIAGNOSES ESTABLISHING METH ODS
3.1 Brief Description of the Existi ng Tests to Detect HPV Infection (WHO HPV
Laboratory Network Data, J uly 2010)
There are two tests available to detect the presence of HPV viral DNA: the Hybrid
Capture II test and the DNA PCR test (Chin-Hong PV & Palefsky JM, 2002). The Hybrid
Capture II test is a more general test that can detect the presence or absence of the high-risk
forms of the virus but cannot specify the subtypes of the high-risk virus. Its advantages are that it
is quick and less expensive compared to PCR tests. The PCR test can detect the type of HPV
present, but sensitivity varies by the type of PCR system used. It is also generally more
expensive and requires the presence of a greater viral load (A Global Review, 2008; SCCA
Vancouver Centre; Canadas MP et aI, 2004).
WHO HPV Laboratory Network (WHO HPV LabNet) developed the manual on exis ting
tests to detect HPV infection based on knowledge and experience gained through its internatio nal
collaborative studies over the past severa l years. HPV cannot be cultured by conventional
methods and is a cell-associa ted virus; therefore HPV infection is monitored indirectly by
detection of HPV DNA in a cellular sample obtained from a particular anatomic site. Lysis with
or without extraction is required to release the viral DNA from the sample. Cellular DNA is also
released at the same time and can serve as a control for the sample adequacy. I-Iuman
papilloma virus (HPV) can be found in human epithelia in two forms, either individu ally or in
combination: episomal or extrachromosomal HPV particles and integrated into the human
genome (Cooper K & Herrington CS et al, 1991).
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It was shown in previous studies that HPV DNA is present in three morphologically
distinct forms in the nuclei of cerv ical precancerous and cancero us lesions by non-isotopic in situ
hybridization (NISH) (Cooper K, et al, 1991). These forms were referred to as NISH signals
types I, 2, & 3, where a type I signal is diffuse and present throughout the nucleus and
represents episomal HPV virus. A type 2 signal is punctuate and represents integrated HPV
virus, and a type 3 signal is a combin ation of both forms. Therefore, a pattern regarding the
physical state of the HPV DNA in Cervical Intraepithelial Neoplasia (CIN) and Squamous Cell
Carcinoma (SCC) is that of episomal HPV virus predominatin g in the early stages of CIN and
SCC, with integrated virus being detected more frequentl y in HPV-related high grade CIN and
SCC. Furthermore, the latter mayor may not contain episomal forms as well (Lehn H et al, 1988;
DiLuca D et ai, 1989). It should be kept in mind that detection of HPV DNA usually indicates
current infection, but surface contamination cannot be excluded. Similarly, failure to detect HPV
DNA does not exclude HPV infection , as low-level infections, sampling errors and infections at
other anatomic sites need to be excluded.
HPV infection is not treated, so current uses of HPV testing in screening and clinical
diagnosis are directed towards detection of HPV-associated precancers that are treated, rather
than to diagnose infection per se. HPV cannot be easily propagated by standard in vitro culture
systems, and in malignant tissue there are little or no infectious HPV particles. For these reasons,
methods are based on the detection of HPV nucleic acids, in most assay formats, HPV DNA.
Molecular methods for HPV detection can be grouped into two main categories:
• Those that rely on signal amplification to detect the targets
• Those that rely on target amplification itself.
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The WHO HPV LabNet has perform ed a series of proficiency testing studie s since 2007.
In total , 81 data sets with HPV typing data were returned to World Health Organization for
evaluation . These different assays used are detailed in Table 16. Briefly, in this study, the Roche
Linear Array was the most widel y-used assay, with result s report ed by 15 laboratori es. The
WHO HPV LabNet has agreed that a laboratory that perform s HPV DNA detection and typing
be considered proficient if it is able to detect 50 International Units (IU)/5JlL of HPVI 6 and
HPV18 DNA , and 500 genome equivalent s (GE)/5JlL of other HPV types; plus, if it also does
not give more than I false-p ositive result (FP) in the panel. It was recommended that genot yping
assays should detect , at a minimum , the fourteen most common high-ri sk (HR) HPV types
(16 ,18,31,33,35,39,45 ,51,52,56,58,59,66 & 68) and the two low-ri sk (LR) HPV types targeted by
a current HPV vaccine (6 & 11) (Meijer CJ. et ai, 2009).
In view of the variety of HPV DNA detection and genotyping assays being used by
laboratories worldwid e, it is necessary validate the assays for both qualit ativel y and
quantit atively to determ ine their : Sensitivity/Limit of Detection , Specificity, Accuracy ,
Reproducibility, Robustn ess, Linearit y, and Analytic Range (International Committee on
Harmoni zation , ICH Validation of analytical procedures: text and methodology)
http: //www.emea.europa.eu/pdfs/human/ich/038195en.pdf
3.2 HPV Genotyping Tests used in this Study
The Nati onal Microbiol ogy Laborato ry, PHAC in Winnipeg, MB condu cted HPV DNA
and genotyping analysis for our study . Two HPV assay types were used (# 1 and #18 in the Table
16) for this purpo se: The Linear Array Genotyping Test (# 1) and The Lumine x®-Ba sed
Genotyping Assay (#18 - In-hou se PCR Luminex L1 (PGMY -GP) . They used supplies from the
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Roche Molecular Diagnostics which operates in the U.S. as the legal entity Roche Molecular
Systems, Inc. (Roche Molecular Diagnostics Global website: http://molecular.roche.com /assays).
Roche research assays and PCR technology have been widely used in landmark epidemiology
studies around the world to characterize the incidence and distribution of HPV genotypes and for
classification of the HPV types as they relate to cervical cancer.
The Linear Array HPV Genotyping Test is a qualitative in vitro test for the detection of
human papillomavirus in clinical specimens. The test utilizes amplification of target DNA by the
Polymerase Chain Reaction (PCR) and nucleic acid hybridization and detects 37 anogenital HPV
DNA types in cervical cells collected in PreservCyt solution (PreservCyt is a registered
trademark of Cytyc Corporation, owned by Hologic). The Linear Array HPV Genotyping Test is
registered for use in the European Union for detection of 37 high- and low-risk human
papillomavirus genotypes, including those considered a significant risk factor for HSIL
progression to cervical cancer (numbers typed in bold). HPV genotypes include:
6,11,16,18,26,31,33,35,39,40,42,45,51,52,53,54,55,56,58,59,6 1,62,64,66,67,68,69,70,71,72,73
(MM9), 81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP6108.
In summary, the Linear Array assay:
• Has superior ability to detect HPV DNA with low and high P-globin references lines.
• Is capable of detecting HPV genotypes in a multiple infection, which can occur in up to
35% of patient samples (Van Hamout D et ai, 2009).
• Has superior ability to detect HPV DNA and individual types that may be attributed to
the use of:
I . Standardized, quality-controlled reagents
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2. Primer concentrations that minimize competition due to coamplification.
(Coutl ee F et aI, 2006).
The Luminex®-Based Genotyping Assay was developed by a team of specialists from
NML, PHAC, Winnipeg, MB; Cadham Provincial Laboratory , Manitoba Health and Healthy
Living, Winnipeg , MB; PHL, St. John ' s, NL; Department of Medical Microbiolog y, University
of Manitoba , Winnipeg , MB. This assay can type simultaneou sly 45 mucosal HPV genotypes
and was evaluated with the Roche Linear Array (LA) test. In this study, amplified single
stranded HPV DNA carrying a biotin tag was generated using primers PGMY (Gravitt PE et aI,
1998) and GP5+/GP6 + (Husman AM et aI, 1995) in a nested PCR reaction; a set of 45 Luminex
microspheres coupled with 45 unique HPV probes was used for detection and typing. A total of
149 cervical specimens collected in PreservCyt were utilized in the study. The Luminex method
identified 45 vs. 37 mucosal HPV types without vs. with cross hybridization as compared to the
Linear Array. It showed a higher sensiti vity than LA test, 85 vs. 73 positive samples , and 171 vs.
164 total HPV types detected, respectively, with 47 multiple infections detected with both
method s. On the other hand, the LA test showed slightly better sensitivity for detecti on of
mult iple infection s with 3 or more types. Discordant samples included 12 Luminex positive/LA
negative results and 36 multiple infections in which the list of types was partially different
between the two methods. Four of these samples contained types not detected by the LA probes.
No sample was completely discordant for HPV typing . The overall distribution of HPV types
was similar between the two methods , with the exception of HPV 52, which was less frequently
detected by the Luminex method (8 vs. 18).
In conclu sion, the tested Luminex assay, while comparable to the Linear Array (LA) test,
offers more flexibility , lower cost and less hands-on time (Goleski VA et al, 2008).
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3.3 Cytopathology
In our study The 2001 Bethesda System (TBS 2001) terminology was used to report the
anal, oropharyngeal and cervical specimens' cytology test results.
Forty-four international organizations with interest in cervical cytopathology cosponsored
the Bethesda System 2001 Workshop along with the National Cancer Institute (NCI) in April
2001. The goal of the Bethesda System has always been to promote effective communication of
relevant cytology findings between the laboratory and clinician to provide optimal patient care.
The Bethesda System was developed primarily for cervical cytology specimens , and both the
terminology and morphologic criteria reflect these. However, specimens from other sites such as
the throat, vagina, and anal-rectal samples may be reported using similar terminology (Solomon
D & Nayar R, 2001).
The Bethesda System's Second Edition provides a clearer indication of adequacy;
specimens are now designated as "Satisfactory" or "Unsatisfactory" for evaluation:
I. For "Satisfactory" specimens, information on transformation zone (TZ) sampling and
other adequacy qualifiers are included.
2. For "Unsatisfactory" specimens, information on whether or not the laboratory has
processed/evaluated the slide are included (specimen rejected or specimen processed
and examined, but unsatisfactory for evaluation because of obscuring blood, etc)
An adequate liquid-based preparation (LBP) should have an estimated minimum of at
least 5000 well-visualized/well-preserved squamous cells. For interpretation of adequacy for anal
specimens at least 8 nucleated squamous cells had to be visualized at high magnification (40X)
to be considered adequate (Scholefield JH, et al, 1998; http://iris.ucl.ac .uk/research).
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This was derived using the ThinPrep criteria of 4 cells per HPF and doublin g it as the diameter of
the sample is smaller for SurePath. If the specimen shows a cytologic abnormality it is not
necessary to report a specimen as unsatisfactory as the abnormality is reported independent of
the cellularity when an abnormality is found. Studies of anal cyto logy have not found the
presence of metaplastic or glandular mucosa necessary to reflect sampling of the transformation
zone in contrast to cervical cytology where there needs to be at least two groups of 5 metaplastic
or glandular cells.
The 2001 Bethesda System maintains an equivocal category Atypical Squamo us Cells
(ASC) and simplifies its qualifier s to realistically reflect the inability of pathologists to
accurately and reproducibl y interpret these specimens (the reprodu cibilit y of ASC as an
interpretation is around 40%). All interpretation s of ASC should be qualified as "Of
undetermined significance" (ASC-US) or "Cannot exclude HSIL" (ASC-H). ASC-US is
expected to comprise more than 90% of ASC interpretations in most laboratories. ASC-H is a
designation reserved for the minority of ASC cases (expected to represent less than 10%) in
which the cytological changes are suggestive of HSIL and require clinical investigation such as
high resolut ion anosco py (Solomon 0 et ai, 2001) .
Squamous intraepithel ial lesion (SIL) encompasses the spectrum of noninvasive cervical
squamous epithelial abnormalities assoc iated with HPV. In TBS, this spectrum is divided into
low-grade (LSIL) and high-grade (HSIL) categories. Low-grade lesions encompass the cellular
changes variously termed "HPV cytopathic effect" (koilocytos is) and mild dysplasia or Cerv ical
Intraepithelial Neoplasia (CIN) I. High-grade lesions encompass moderate dysplasia, seve re
dysplasia, and Carcinoma in situ or CIN 2, 3.
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Conceptually, HPV-associated abnormalities can be divided into transient infections that
generally regress over the course of 1 to 2 years and HPV persistence that is associated with an
increased risk of developing a cancer precursor or invasive cancer (Bosch FX et ai, 2002).
Epithelial cell abnormalities require further investigation such as colposcopy or high
resolution anoscopy (HRA) with biopsy. These abnormality categories along with the
recommended management are demonstrated in Table 16. This Table was revised in January,
2007 with support from the Nova Scotia Gynecological Cancer Screening Program , and
Ontario's Laboratory Proficiency Testing Program Guidelines. Consultation was held with
leading Pathologists and Physicians in the Province of Newfoundland and Labrador , and was
endorsed by the NL Medical Association (Cervical Screening Initiatives Program 2007, Clinical
Management Guidelines). These Guidelines were used in our study for follow-up and





In this cross-sectional study the baseline measurements ofCD4 cell count and viral load were
analyzed. The 12-item clinical questionnaire (Appendix D) included only the primar y data (at the
baseline visit) and did not include data related to these parameters mean , median , nadir , and
range measurements. The collected data was categorized. CD4 cell counts were divided on two
categories: CD4 count < 200 cells/ml and CD4 count 2::200 cells /m!. This was done based on
evidence from different studies of oral opportunistic infection s in adults with HIV/AIDS. Oral
opportuni stic infections such as Kaposi 's sarcoma (100%; p=0.035) , candidiasi s (82.2 %; p<
0.001) , linear gingival erythema (70.0%; p=0.OI5) , hairy leukoplakia (66.3 %; p<O.OOI ), and
others were strongly associated with immune suppression and were found to be significantly
correlated to a reduced CD4 cell count below 200 cells/ml , thus serving as potential clinical
markers of HIV viremia and progressive HIV disease (p<O.OOI; OR=3.1; 95%CI 1.9-4.9)
(Bodhade AS, Ganvir SM & Hazarey VK, 20 II ; and Patton LL, 2000).
Plasma viral load was categorized according to four levels: 0 - "Never had test" ; I -
"Undetectable level at :S50 copies /ml"; 2 - "Detectable level at >50 copies/ml"; and 3 -
"Unknown". These categories are widely used by medical practitioners working with HIV-
positive adults and participating in the study as co-investigators. IBM® SPSS 19.0 was used for
the statistical analyses . All tests were two-sided with the significance at u<0.05. The following
analyses were conducted:
1. Frequency count s of the patient's demographic information
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2. Frequency counts of the different presentation ofHPV genotypes
3. Frequency counts of oncogenic disease activity (pre-cancer lesions and cancers of the
oropharynx, cervix, anus, vulva, vagina, and penis)
4. Calculation of the association between disease expression and genotype presentation
(Chi-Square, Logistic Regression)
5. Calculation of the association between the underlying risk factors and oncogenic activity
(Chi-Square, Logistic Regression)
6. Calculation of the prevalence rates ofHPV genotypes and oncogenic activity
The study population was normally distributed by provinces and participants' age
(Histograms 1 & 2) and was skewed to the right by gender because of the prevalent male
population . Of 300 patients included in the analysis 91.7% were males. The population and
gender distribution among the provinces were: NSH - total 150 patients, of these 142 (94.7%)
were males; NBM - total 90 patients, of these 85 (94.4%) were males; NLS] - total 44 patients,
of these 34 (87.3%) were males; and NBS] - total 16 patients, of these 14 (87.4%) were males.
The overall mean (SD) age of the participants was 46.9 (9.36) years and the distribution of the
study population was: 62 (20.7%) aged 25 to 39 years; 209 (69.7%) aged 40 to 59 years; and 29
(9.6%) aged 60 years and older (Table 1).
Of 300 patients, 90.3% vs. 9.7% were on anti-HIV treatment previous to the study (p=0.006);
and 86.7% vs. 13.3% were on anti-HlV medication at the screening year of the study with
p=0.044. The majority of participants (73.0% vs. 27.0%) did not have an AIDS-defining event
previous to the study (p=0.660); while 97.0% of them vs. 3.0% did not have any AIDS-defining
event at the screening time (p=0.738).
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Histogram 1
Distribution ofthe Population by Provinces
X-ax is: I. NLSJ ; 2. NBI\I; 3. NSB; 4.NBSJ
Y-axis: Numberof l'a rt icipants
Histogram 2
Distribution ofthe Population by Age (in years)
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TABLE 1
Distribution ofthe Study Population by Gender, Age Categories & by
Provinces
Pro vinces Age Categories
GENDER NLSJ NBM NSH NBSJ TOTAL 25 -39 .0 40 -59 .0 . 60& > .0 . I' -Valu e
34 85 142 14 275 50 200 25
MALE (12.4%) * (30.9%) (51.6%) (5.1%) (~~J~* (80.6%) *** (95.7%) (86.2 %)77.3% ** 94.4% 94.7% 87.5% < 0.00 1
10 5 8 2 25 12 9 4
FEMALE (40.0%) * (20.0%) (32.0%) (8.0%) (100%) * (19.4%) *** (4.3%) (13.8%)
22.7"10 ** 5.6% 5.3% 12.5% 8.3%
44 90 150 16 300(100%) 62 209 29
TOTAL (100%) ** (100%) (100% ) (100%) (100%) *** (100%) (100%)
Percenta ge of Total Study Population Genders.
Percenta ge of Genders in each Province
Per centa ge of Genders in each Age Category.
None of the study participants had been vaccinated against HPV infection. Of the 300
participants , 283 (94.3%) were born in Canada; 6 (2.0%) were from the United States of America
(USA); 3 (1.0%) - from the United Kingdom (UK); I (0.3%) from New Zealand; I (0.3%) from
Germany and 6 (2.0%) patients were from African countries. Of the 300 patients, 288 (96.0%)
were white Caucasians; 3 (1.0%) were black Africans and 3 patients had aborigina l background;
the remaining 6 (2%) patients were each from other ethnic backgrounds. About half of the study
population (49%) had a high level of education : 110/300 (36.7%) patients had college/university
education and 37/300 (12.3%) had graduate degrees. The remaining 51% of the study population
had an education level from elementary school to high school diploma.
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According to smoking status, the study population was distributed as follow: 132 (44.0%)
patients smoked daily or occasionally; 83 (27.7%) used to smoke but quit; and 85 (28.3%) never
smoked prior to the study.
Of the 300 patients, 245 (81.7%) never had an anal Pap test; 33 (11.0%) patients had it at
some point of their life but their results were known neither to the patients nor to their current
physicians; and 22 (7.3%) patients were not sure. On the question whether they ever had sex, 292
(97.3%) participants answered "yes"; 7 (2.3%) answered "no"; and I (0.3%) answered "don 't
know". The declared number of male sexual partners during the last year varied from "none"
(116 (38.7%)) to 50 (I (0.3%)). The majority of the participants had one male partner during the
year (100 (33.3%)). The declared number of female sexual partners varied from "none" (266
(88.7%)) to 10 (I (0.3%)). The majority of the study participants (245 (81.7%)) had anal sex with
condoms during the last year. The number of the patients who had oral sex with condoms (or did
not practice it at all) and who did not use condoms for oral sex was almost equal (146 (48.7%)
vs. 154 (51.3%), respectively).
All 25 female participants had been screened previously for cervical cancer within
different time intervals from a last test. Of the 25 females, 7 (28%) were in each of the following
categories : " less than 6 months ago" and "from I year to less than 3 years ago". Four (16%)
females had the test within the last year; three (12%) women had it "from 3 years to less than 5
years" ; one (4%) woman was last screened "5 and more years ago"; and one of them did not
remember. Of the 25 women, 18 (72%) used or were still using oral contraceptives (OC). Four
females (16%) had a history of precancerous lesions and cervical cancer prior to the study (there
was a lack of information about the types of lesions). Of these, two females had a hysterectomy
and the specimens for their Pap test were collected from their vaginal vaults
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for potential vaginal lesions. The patients' self-reported history of sexually transmitted infections
(STIs) was also studied.
Sexually transmitted infection is an infection that can be transferred from one person to another
through sexual contact. In this context, sexual contact is more than ju st sexual intercourse
(vaginal and anal) and also includes kissing, oral-genital contact, and the use of sexual "toys,"
such as vibrators (http://www.medterms.comL).
Of 300 HIV-positive participants, 107 (35.7%) never had STIs other than HIV; 94
(31.3%) patients had a history of one STI; 46 (15.3%) had a history of two STIs; 23 (7.7%)
mentioned three STIs; 16 (5.3%) had a history of four STIs; 2 (0.7%) had five STIs, and one
patients had six of them; 12 (4.0%) patients were not aware of their history of sexually
transmitted infections. The most common STI was ano-genital warts: 106 (35.3%) patients
currently have or had previously had them. According to the data from the patient' s
questionnaire: 32 (10.7%) had Hepatitis Band 31 (10.3%) - Hepatitis C. The history of other
STIs among the patients was distributed as follow: 28 (9.3%) had Chlamydia; 70 (23.3%) -
Gonorrhea; 32 (10.7%) - Syphilis; and 46 (15.3%) patients had a history of Genital Herpes.
A few questions were related to the patient' s awareness about HPV infection and its
causative relationship with genital warts and/or cervical cancer. Of 300 patients, 232 (74%)
indicated they knew nothing about it at all; and 41 (13.7%) patients were sure that HPV does not
cause warts and/or cervical cancer. Of all participants, 147 (49%) had never heard about the
HPV vaccine, and 19 (6.3%) participants checked "false" when responding to the statement
"HPV vaccine can lower risk for warts/cancer". Finally, 245 (81.7%) patients believed that the
Pap test is still extremely/very important for women vaccinated against HPV infection; and 263
(87.7%) patients believed in the importance of the practicing safe sex for those who have
received the HPV vaccine. 34
4.2 Study Outcomes
Among the 300 participants, a total 46 HPV genotypes were detected. Of them, 18 (39%)
were high-risk (HR) types and 28 (6 1%) low-risk (LR) types. The total number of detected HPV
infections was 801. Of 300 patients, 232 (77.3%) were "positive" for HPV infection and of
these, 125 (54%) were infected with ~3 HPV types: 98 (78.4%) of these patients had from 3 to 6
HPV genotypes; 24 (19.2%) from 7 to 10 HPV types; and 3 (2.4%) from I I to 14 HPV
genotypes. The highest number of HPV genotypes in one case was 14 (Ta ble 2 & Chart 1).
TABLE 2
Distribution ofHPV Genotypes in the Study Population
HPVType 1 HPV 2HPV 3-6 HP V 7-10 HPV 11-14 HPV Tota l
Low-Ri sk (LR ) 375***
HP V 41 52 173 92 17 (46.8% )
Probably High- 64***
Risk (PHR) HP V 5 6 36 14 3 (8.0%)
High-Risk (HR ) 362***
HP V 12 40 208 86 16 (45.2%)
T otal # of 801****
Infections 58 98 417 192 36 (100% )
58* 49* 98* 24* 3* 232**
Tota l # of Cases (25.0%) (21.1% ) (42.2%) (10.3%) (1.4%) (100%)
Number of Cases of the detected HPV Type s.
Total Number of HPV-Po sitive Cases.
Number of HPV Infections (LR, PHR & HR).
**** Total Number of the detected HPV Infections.
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Chart 1









6 1116 1831 32 33 35 39 42 45 5152 53 54 55 56 58 59 61 6266687072 73 84
Y axis - number of cases with particular HPV type; X axis - detected HPV types.
LR HPV genotypes are light-colored
HR HPV genotypes are dark-colored
In this study we analyzed only HR HPV genotypes and the most frequently detected HR
HPV types were: HPV16 11.8% (74/625); HPV52 7.2% (45/625) ; I-1PV45 5.6% (35/625) ;
HPV51 5.4% (34/625) & HPVI8 /HPV59 4.55% each (28/625) . The distribution of the HR HPV
genotypes by both gender and age categories is showed in the Table3.
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TABLE 3
Distribution ofHigh-Risk HPV Genotypes
By Gender & Age Categories
Fisher 's
Exact
TOTAL GENDER Test AGE CATEGORIES Pearson,/!
# of
HPVTYPE CASES Male Female P-Value 25-39 y.o. 40-59 .0. 60& >y.o. P-Value
69 5
HPVI6 74 (25.1%) (20.1%) 0.386 16(25.8%) 52(24.9%) 6(20.7%) 0.863
25 3
HI'VI8 28 (9.1%) (12.0%) 0.716 10(16.1 %) 17(8.1 %) 1(3 .4%) 0.085
17 2
HPV31 19 (6.2%) (8.0%) 0.665 4(6 .5%) 15(7.2 %) 0(0.0%) 0.331
13 0
HPV33 13 (4.7%) (0.0%) 0.611 5(8.1%) 7(3.3%) 1(3.4 %) 0.269
20 3
H1'V35 23 (7.3%) (12.0 %) 0.422 4(6.5%) 17(8.1 %) 2(6.9%) 0.897
24 I
NPV39 25 (8.7%) (4.0%) 0.707 7(11.3%) 16(7.7 %) 2(6.9%) 0.633
33 2
HPV45 35 (12.0 %) (8.0%) 0.751 8(12.9%) 24(11.5%) 3(10.3%) 0.929
31 3
HI'VSI 34 (11.3 %) (12.0 %) I 12(19.4 %) 22(10.5%) 0(0.0%) 0.02
39 6
HPV52 45 (14.2%) (24.0 %) 0.236 8(12.9%) 32(15.3%) 5(1 7.2%) 0.842
23 2
HPV53 25 (8.4%) (8.0%) I 5(8.1 %) 17(8.1 %) 3(10.3%) 0.918
17 2
HPV56 19 (6.2%) (8.0%) 0.665 4(6 .5%) 14(6.7 %) 1(3.4 %) 0.796
14 2
HPV58 16 (5.1%) (8.0%) 0.632 2(3.2%) 11(5 .3%) 3(10.3%) 0.37
27 I
HPV5 9 28 (9.8%) (4.0%) 0.489 8(12.9%) 19(9.1 %) 1(3.4 %) 0.344
23 I
HI'V62 24 (8.4%) (4.0%) 0.705 9(14.5%) 9(4.3%) 6(20.7%) 0.001
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Significant differences were detected only in association with HPV51 and the first age
category: 12 (19.4%) from 62 patients had this genotype (p=0.020); and between HPV62 and the
third age category : 6 (20.7%) from 29 patients had this genotype (p=O.OOI) . The analysis of the
association of the HR HPV genotypes with the Anal Cytopathology demonstrated significance
(Pearson X2) in the prevalence of I-1PVI6 (p<O.OOI), HPV45 (p=0.044), HPV51 (p=0.014),
HPV52 (p<O.OOI), HPV53 (p=0.045), and HPV59 (p=0.006). The Logistic Regression analysis
showed that the following genotypes were less likely to be associated with anal precancerous
lesions: HPV59 (OR=O.363; p=0.044; 95%CI 0.135-0.974); HPV52 (OR=O.1l 2; p<O.OOI;
95%CI 0.042-0.313), HPV53 (OR=O.206; p=0.004; 95%CI 0.070-0 .611); while HPV35
genotype was strongly associated with the Anal LSIL cytologic changes (OR= IO.180; p=O.OII;
95%CI 1.705-60.795). There was no significant difference in the association of HPV genotypes
with the Anal HSIL cytologic changes due to the small sample size (Table 4).
38
TABLE 4
Association ofHigh-Risk HPV Genotypes with Anal Cytology
HPVTYPE ASC- ASC-H LSIL HSIL NILM UNSAT Pearson x:(PREVALENCE) us
P-Value
HPVI6 (74) 15 1 16 3 32 7 < 0.001(40.5'10) (33.3%) (45.7'10) (100%) (18.3%) (15.25)
HPV18 (28) 6 0 7 0 12 3 0.163(16.2%) (0.0%) (20.0%) (0.0%) (6.9'10) (6.5%)
HPV31 (19) 5 1 2 0 8 3 0.23(13.5%) (33.3%) (5.7%) (0.0%) (4.6%) (6.5%)
HPV33 (13) 3 0 1 1 7 1 0.218(8.1%) (0.0%) (2.9%) (33.3%) (4.0%) (2.2%)
HPV35 (23) 6 1 2 0 13 1 0.168(16.2%) (33.3%) (5.7°1..) (0.0%) (7.4%) (2.2%)
HPV39 (25) 3 0 6 1 13 2 0.275(8.1%) (0.0%) (17.1%) (33.3%) (7.4%) (4.3%)
HPV45 (35) 8 0 7 0 20 0 0.044(21.6'10) (0.0%) (20.0'X.) (0.0% ) (11.4%) (0.0%)
HPV51 (34) 7 0 5 1 19 1 0.014(18.9%) (0.0%) (14.3%) (33.3%) (10.9%) (2.2%)
HPV52 (45) 9 1 14 0 17 4 <0.001(24.3%) (33.3%) (40.0%) (0.0%) (9.7%) (8.7%)
HPV53 (25) 1 0 7 1 15 1 0.045(2.7%) (0.0%) (20.0%) (33.3%) (8.6%) (2.2%)
HPV56 (19) 4 0 5 0 9 1 0.301(10.8%) (0.0%) (14.3%) (0.0%) (5.1%) (2.2%)
HPV58 (16) 4 1 3 0 6 2 0.165(10.8%) (33.3%) (8.6%) (0.0%) (3.4%) (4.3%)
HI)V59 (28) 8 1 6 I 11 1 0.006(21.6%) (33.3%) (17.1%) (33.3%) (6.3%) (2.2%)
NILM - Negallve for Intraepithelial lesion
ASC -US/ ASC -H-A typ ical Squamous Cells Undetermined Significance/Ca nnot Exclude High-grade lesions
LSI L- Low-grade Squamous Intraepitheliall esion
HSI L-Hi gh-grade Squamous Intraepitheliall esion
UNSAT- Unsatisfactory for evaluation specimen
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A significant assoc iation of the HR HPV genotypes with the Oropharyngeal Cytopathology
(ASC-US) was detected (Pearson X2) with HPV51 (p=0.042). The analysis of the assoc iation of
the HR HPV genotypes with the Cerv ical Cytopathology (LSIL/HSIL) demonstrated significance
with I-IPV35 (p=0.029) . The Logistic Regression analysis did not show significance for the same
assoc iations.
The comparative analysis of the Sensitivity of the two PCR Assays (Luminex®-Based
Genotyping Assay vs. Linear Array Assay (LA)) was presented by column charts and displayed
below. The study results confirmed the assays characteristics provided by the WHO HPV
LabNet Database. The Luminex®-Based Assay generally detected more cases in the presence of
I or 2 HPV genotypes compared to LA (46.3% (139) vs. 28.7% (86), respectively), while LA
detected comparatively more HPV genotypes in the presence of multiple infections (35% vs.
23%) amo ng the anal samples. (Ta bles 5, 6 & 7 with Column-Charts 2 & 3; 4 & 5; and 6 & 7)
A total of 625 cytology reports were collected in the screening year from 300 A (anal),
300 0 (oropharyngeal), & 25 C (cerv ical) specimens. The cytology analysis of the specimens
showed that abnormalities were mostly detected among the anal specimens (78 (26%)) . All
abnormal reports have been categorized by the specimen type and detected changes (percentage
for totals within the total specimens' number (625); percentage in a particular specimen type
within this specimen), one cervica l L-HSIL case was class ified as HSIL:
• ASC-US: total number was 39 (6.2%): A-37 (12.3%); 0 -1 (0.3%) ; C- I (4.0%)
• ASC- H: total number was 3 (0.5%) and all 3 (1.0%) were among anal specimens
• LSIL: total number was 36 (5.8%), from them: A-35 (11.6%) and C- I (4.0%)
• HSIL: total number was 4 from 625 (0.6%), from them A-3 (1.0%) and C- I (4.0%)
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TABLE 5
Distribution ofthe HPV Genotypes in Anal Specimens
Number ofCases Luminex Linear Array
Total 300 300
Positive for HPV infection 208 (69.3%) 2//(70.3%)
Negative for HPV infection 92 89
1 HPVtype 79 53
2 HPVtypes 60 43
3& > HPVtypes 69 (23%) 104(35%)
Max Detected HPV Types ill I Case 8 12
Inconclusive 0 //













Distribution ofthe HP V Genotypes in Oropharyngeal Specimens
Number ofCases Lumin ex Linear Array
Total 300 300
Positive for HP V infection 21 12
Ne/!ativef or HP V infection 279 277
1 Hp n vpe 17 8
2 HP Vtyp es 4 4
3 & > HP Vtyp es 0 0
Max Detected HP V Types in 1 Case 2 2
Inconclusive 0 Jl









Distribution ofthe HPV Genotypes in Cervical Specimens
Number of Cases Luminex Linear Array
Total 25 25
Positivefor HP V infection 14 8
Negativefor HP V infection II 16
I HP V type 10 3
2 HPVtypes 4 4
3 & > HP Vtypes 0 I
Max Detected HP V Tvpes in I Case 2 5
Inconclusive 0 I







From 625 specimens, 497 (79.5%) were negative (NILM) for intraepithelial lesions, of these:
A-176 (35.4%); 0-299 (60.2%); & C-22 (4.4%). Seventy three (24.3%) anal specimens were
primarily unsatisfactory for the cytology evaluation. During the year, 27 of them have been
recollected with the following final reports: NILM - 18, ASC-US - 4, LSIL - 3, and 2 of them
were repeatedly reported as unsatisfactory for evaluation. The remaining 46 unsatisfactory
(15.3%) anal samples were not evaluated in the screening year (Table 8 & Chart 8).
TABLE 8
Cytology Results in the Study Cohort
Type of Specimen
Cytology
Result ANAL ORAL CERVI CAL TOTAL
ASC-US 37 (12.3%) * 1(0.3%)* 1 (4.0%) * 39(6.2%)**
ASC-H 3(1.0%) 3 (0.5°1..)
LSIL 35 (11.7'X.) 1 (4.0%) 36 (5.8%)
HSIL 3(1.0%) 1 (4.0%) 4(0.6%)
NILM 176 (58.6%) 299 (99.7%) 22 (88.0%) 497 (79.5%)
UNSAT 46 (15.3%) 46(7.4%)
TOTAL 300 (100%) * 300 (IOO'Yo) 25 (100%) 625(100%)**
* Percentage of the total number of each Specimen
** Percentage of the total number of the Cytology Reports
44
Chart 8
Cytology Result s by Sp ecimen Typ e





The analysis of the association between cytology reports and age categories showed no
significance except for cervica l ASC-US changes in the age category from 25 to 39 years with
p=O.OIO (Table 9).
TABLE 9
Cytology Results (Number & Percentage) within Patients '
Age Categories
C~~~~I~Y ANAL OR AL CE RV ICAL25 -39 ~O -59 60& > P 25 -39 ~0 - 59 60& > P 25 -39 ~O - 59 60& > I'
ASC-US 7 27 3 0.930 I 0 0 00489 I 0 0 11.1111111.3% 12.9% 10.3% 1.6% 0.0% 0.0% 8.3% 0.0% 0.0%
ASC-H 0 3 0 0 0 0 0 0 00.0% 1.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
LSIL 5 27 3 0 0 0 0 I 08. 1% 12.9% 10.3% 11.0% 0.11% (1.(1% 0.0% 12.5% O.lI%
HSI L 0 3 0 II 0 0 I 0 0lI.lI% 1.4% lI.O% O.lI% 0.0% lI.lI% 8.3% lI.lI% O.O°t'o
NILM ~I 118 17 61 209 29 10 7 5(66.1%) (56.5%) (58.6%) (98.~ 'V.) (100%) (100%) (83.~%) (87_~·1o) (100'1'.)
UNSAT 9 31 61~.5% 1 ~ .8% 2l1.7%
TOTAL 62 209 29 62 209 29 12 8 5100% 100% 100'1'. 100% 100·/0 100% 100% 100% 100 0/.
Among 300 oropharyngeal samples only one (female patient) was read as ASC-US, all others
were negative (NILM) for intraepithelial lesions.
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TABLE 10
Cytology Results (Number & Percentage) within Patients' Gender
ANAL ORAL
CYT O LOG Y
RESULT MAL E FEM AL E P MAL E FEM AL E P CE RVICAL P
ASC-US 35 2 0 I I(12.7%) (8.0%) 0.482 (0.0%) (4.0%) 0.010 (4.0%) <0.001
ASC- H 3 0 0 0 0(1.1% ) (0.0%) (0.0%) (0.0%) (0.0%)
LSIL 35 0 0 0 I(12.7%) (0.0%) (0.0%) (0.0%) (4.0%)
HSIL 3 0 0 0 1(1.1%) (0.0%) (0.0%) (0.0'10) (4.0%)
NILM 158 18 275 24 22(57.5%) (72.0%) (100%) (96.0%) (88.0%)
UNSAT 41 5(14.9% ) (20.0%)
TOTAL 275 25 275 25 25(100% ) (100% ) (100%) (100%) (100%)
The association of the anal cyto logic abnormalit ies with the underlying risk factors (smokin g,
number of sexual partners during the last year, practicing in unprotected sex) was not significant ;
while the assoc iation of those with a history of sexua lly transmitted infections was almost-
significant for ano-gen ital warts compared to other STls (p=O.054) (T able 11).
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TABLE 11
Association ofAnal Cytology Results with Underlying Risk Factors
Table ItA: Smoking Status
Anal Smoking Used to SmokeCytologic Smoking Daily Not Smoking P-Value
Abnormalities Occasionally but Quit
ASC-US 19(51.4%) 2(5.4%) 6(16.2%) 10(27.0%) 0.277
ASC-H 1 (33.3%) 1 (33.3%) 1 (33.3°1..) 0(0.0%)
LSIL 18(51.4%) 4(11.4%) 6(17.1%) 7(20.0%)
HSIL 2(66.7%) 0(0.0%) 1 (33.3'X.) 0(0.0%)
Table 118: History ofSexually Transmitted Infections (STIs)
Ano-Genital Warts
Anal
Cytologic Neither had nor have warts Had previously or have currently P-Value
Abnormalities
ASC-US 16(43.2%) 21 (56.8%) 0.054
ASC-H 3 (JOO%) 0(0.0%)
LSIL 17(48.6%) 18(51.4%)
HSIL 2(66.7%) 1 (33.3'10)
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The association between cyto logic abnorma lities and a history of unprotec ted sex was also
evaluated. A trend toward a significant differe nce was detected within Anal specimens: 25
(67.7 %) of ASC-US changes were related to patient s who practiced safe anal sex (p=O.055), and
33 (89.2%) of all ASC- US change s were detected in patient s who had safe vaginal sex or did not
practice this kind of sex at all (p<O.OOI). The majority ofNILM result s associated with condom
use in any kind of sexual intercourse (T able 12).
TABLE 12
Association ofCytology Results with the Patients' History of
Unprotected (Anal, Oral & Vaginal) Sex
ANA L ORAL VAG INA L
Type or TY I'Eor NO CON110M I' NO CONIIO M I' NO CON 110M I'Speci men REI' ORT CO NI>OM CONIIO M CON110M
ASC-IJS 12 (32J%) 25(6 7.7%) 0.055 19 (51.4"10) 18 (48.6% ) 0548 3(8 .1%) 33 (H9.2%) 0.766
Anal ASC· II 3( 100%) 3(100~"1 3( 100~.)
Cylol"l:) ts n, 7 (20.0~.) 28(80.0 %) 18(5 1.4%) 17 (48.6% ) 35(100~.)
IISII . 0(0 .0%) 3( 100%) I (33J%) 2((>6.7~.) 3 (I()(I%)
NID I 28(16.1%) 1 46(83.9~.) 1I (6J~.) 164(93.7% ) 88(50J%) 87(49.7~.)
ASC-IJS 1 (100% ) 0.181 I( IOO~.) 0_~12 0.946
Oro pharyngea l ASC-II
Cy tology 1$1 1.
IISI L
NIUI 53(17.8%) 244(82.2%) 16(5.4% ) 283(94.6%) 146(49.0% ) 152(51.0% )
ASC-I IS 1 (100% ) O.I M 1 ( 100~.) 0.171 < 0.00 1
Cervical ASC- II
Cyloh'l:Y rsn , 1 (100% ) 1 (100% , f (IlHI"/o)
IISII . 1 (100% ) 1 (100% ) 1 ( I()(I%)
NII.M 52 19.0% 222(81.0%) 140 50.9% ) 1354 9.1% 82.9%) 26797.1%)
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Number of both male and female sexual partners during the last year was not significantly
associated with cytologic changes. Table 13A displays the correlation for the number of male
partners. Finally, for males no significant differences were detected in the association of
cytologic abnormalities either with patient' s CD4 cells count (p=O.I92) (Table 138 ) or with
their plasma viral load levels (Anal: p=0.493; Oral: p=0.998; & Cervical: p=0.747).
TABLE 13
Association ofAnal Cytology Results with:
Table 13A: The Number ofMale Partners during the last year
# of Male ASC-US ASC-H LSIL HSIL NILM P-Partners VALUE
None 13 (35.1'Yo) 1 (33.3°1..) 13 37.1%) 1 (33.3%) 61 (34.9%) 0.734
1 14(37.8%) 1 (33.3%) 12 34.3%) 1 (33.3%) 60 (34.3%)
2 12.7%) 3 8.6%) 15 8.6%)
3 -5 5 (13.5%) 1 (33.3%) 5(14.3%) 23(13.1%)
6 -10 3 8.1%) 2 5.7%) 1 (33.3%) 7(4.0%)
> 10 1(2.7%) o 0.0%) 9(5.1%)
TOTAL 37 (100%) 3(100%) 35(100%) 3(100%) 175(100%)
Table 138: CD4 cell count
CD4cells P-
count ASC-US ASC-H LSIL HSIL NILM VAL UECategor ies
CD < 200 11 (29.7%) 1 (33.3%) 14 (40.0%) 0(0.0%) 41 (23.4%) 0.192
ccIls/ml
CD ~ 200 26 (70.3%) 2(66.7%) 21 (60.0%) 3 (100%) 134 (76.6%)
cells/ml
Total 37 (100%) 3(100%) 35 (100%) 3 (100%) 175 (100%)
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The prevalence rate of HPV-positive cases in the study population was 77.3% (232/300),
from them the prevalence rate of cases with the high-risk (HR) HPV genotypes was 46.6%
(108/232). The overall prevalence rate of cytologic abnormalities caused by HR HPV types in
the study population was 27.3% (82/300) during the screening year, from them the prevalence of
ASC-US cytologic changes was 47.6% (39/82) and ASC-H was 3.6% (3/82); LSILs - 43.9%




5.1 Discu ssion of the Study Result s
In this study we investigated the prevalence of HPV genotypes among I-1IV-positive
adults living in Atlantic Canada . This population is at an increased risk for the development of
pre-cancerous and cancerous lesions compared to the general population. Integration of high-risk
HPV genotypes into the cellular genome is considered an important event in the pathogenesis of
cancer related to the progression from pre-malignant lesions to invasive cancer. It was found that
the target population over a wide age-range had a high rate of the cancer precursor lesions as
determined by cytologic analysis. Given that the previous study conduct ed by Palefsky JM in
2000 showed that anal cytology has only 50% sensitivity for diagnosing HSIL compared with the
gold standard anal biopsy, the true prevalence of HSILs is likely to be even higher than what is
reported here (Panther LA et ai, 2004; de Ruiter A et aI, 1994). Cyto logy is well recognized to
miss cases of HSIL, but some of the cases of LSIL and ASCIASC-H could potentially be I-1 SIL
on follow up. The overa ll prevalence of HSILs by cyto logy for anus, cervix and oropharynx
reports was 1.3% (4/300); LSILs - 12% (36/300); and ASCs - 14% (42/300). Most HPV
infections are thought to resolve spontaneously; however, we expect that proportions' of our
participants will have a persistent I-1PV infection that may lead to pre-cancerous and cancerous
lesions (CS ILs), the incidence of which typically peaks 2-3 years after the initiation of sexual
activity and then drops substantially among older women (A Global Review, 2008) while
continuing to have the same prevalence among older MSM (Burk RD et al, 1996; Herrero et al,
2000; and Szarka K et al, 2009).
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In large studies of HIV-positive males, sens itivity of ana l the Pap test varied from 46%
(95% CI, 360/0-56%) to 69% (95% CI, 60%- 78%), with spec ificity ranging from 59% (95% c i,
530/0- 65%) to 81% (95% CI, 76%-8 5%). In the only study of HIV-negative males (EXPLORE),
the sensitivity of the anal Pap test ranged from 26% (95% CI, 5%- 47%) to 47% (95% CI, 260/0-
68%) , with spec ificity ranging from 81% (95% CI, 76%-85%) to 92% (95% CI, 890/0-95%)
(Walboomers et al, 1999; IARC Monographs, 2004; Mathews WC et aI, 2004; Palefsky JM &
Holly EA, 1997 ; and Salit I et ai, 2006) . Estimates of anal Pap test sensitivity and speci ficity are
highly varia ble, and depend on the varyin g prevalence of cyto logic abnorma lities and differential
thresholds for abnormality by both cytology and histopath ology (Pantanowitz L & Gez ube BJ,
20 10; Highleyman L, 20 10; Friedlander MA et ai, 2004; Panther LA et ai, 2004; de Ruiter A et
aI, 1994). The test is also subject to interpretive variability.
There are very few studies of HPV incidence in Canada, and all have been conducted for
women (http://www .phac-aspc.gc.ca/publica!L). HPV prevalence estimates for women in
countries around the world range from 2% to 44%, depend ing on the geogra phic region,
popul ation sampled and testing methodology (Bosc h FX, de Sanjose S, 2003). A peak prevalence
of HPV infection in women < 25 years of age has been demonstrated consistently, with a
decreasing prevalence with age thereafter (Baseman JG & Koutsky LA, 2005) . In comparison,
cervi cal Pap testing has also been eva luated mainl y in settings where there is a high prevalence
of the disease, and estimates of sensitivity and specificity were also low and highly var iable
(Fahey MT et ai, 1995; Nanda K et ai, 2000). In a systematic review involving cerv ical Pap
testing, sensitivity ranged from 30% to 87% (mea n, 47%) and specificity from 86% to 100%
with mean 95% (Elam G et ai, 2008; Chin-Hong PV et ai, 2009);
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No direct evidence exists to support the effec tiveness of an anal Pap test screeni ng program to
reduce anal cancer mortality or morbidity (Go ldie SJ et aI, 1999). There are, however, strong
parallels with cervical pap testing for cervica l cancer (D'So uza G et ai, 2009) . Sexually
transmitted HPV viral infection is currently an acknowledged common causative agent for both
anal and cervical cancer. Anal cancer rates in high-risk populations exceed those of cervical
cancer before the implementation of Pap testing, and screening tests for these populati ons may
be effec tive in reducing incidence and mortality rates as has been documented with Pap testing.
In the cross-sectional study conducted by Canadas HP et al in 20 10, the overall
prevalence of HPV infect ion in their HIV-positive female cohort was 53% (133/25 1); the most
prevalent genotypes were HPV16 (27%), HPV33 (15%), HPV52 (8%) and HPV 58 (8%).
In this study the overall prevalence of HPV infection among our female population was
higher compared to the study above: 68% (17/25), while the most prevalent genotype was the
same HPV16 - 8% (2/25) . The differences may be attributable to the small study sample. All
other HR HPV genotypes (18, 35, 51 & 58) were distributed at an equal proportion 1/25 (4%
each genotype) . The prevalence of abnormal cervical cytology in the Canadas study was 33%
(83/25 I) vs. 12% (3/25) in our study. Severa l studies have shown that the detection of cervica l
cytology abnormalities (i.e., LSILs & HSILs) is strongly associa ted with age (A Global Review,
2008). Using general populati on-based sampling, Herrero et al in 1997 and 2000 demonstrated
that the prevalence of LSILs in the cervix peaked at 5.2% among women younger than 25 years,
decreased sharply to 2.7% by ages 25-34 years, and then continued to decrease to 0.3% among
women older than 65 years. Herrero R. found that among women less than 25 years of age,
oncogenic HPV types predominated, whereas in women older than 55 years, non-oncogenic and
uncharacterized types were the most common.
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A second peak in HPV prevalence among older women has also been found in some studies
(Young TK, McNicol P & Beauvais J, 1997; Koutsky L, 1997), but this has not been seen
consistently. In our study the mean (SO) age of the female patients was 43.60 (10.17) years. We
detected one cerv ical LSIL in the second age category from 40 to 59 years (4%), and one
cervica l LSILlHSIL in the first age category from 25 to 39 years (4%) . These discrepancies can
be attributed to a small number of female participants in our study cohort as well as to the fact
that four females had been previously diagnosed with cervical pre-cancerous lesions and cancer
and treated (two women had a hysterectomy and the Pap smear in the study was collected from
their vaginal vaults) prior to their enrollment into the study.
It was hypothesized an increasing proportion of men would develop ASILs in the older
age groups because of the absence of the screening for anal cancer and subsequent treatment of
disease previously to their enrolment to the study.
The "EX PLORE" study was conducted by Chin-Hong PV et al. in 2004 to investigate the
age-assoc iated prevalence of HPV-related anal cytologic abnormalities in MSM. The study
reported that there is no age-assoc iated prevalence of ASILs (Anal Squamous Intraepithelial
Lesions) in MSM. These facts suggest that many of the lesions that develop after HPV infection
are transient and are distribut ed similarly among all age groups. The overall prevalence of anal
abnormal cytology (ASC-US & ASC-H, LSILS, & HSILs) in this study at baseline was 12.3%
and 1.0%; 11.7% and 1.0%, respectively and was almost similar for all age categories. The test
of trends is demonstrated on Graph # 1.
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Graph 1
Distribution of Anal Cytology Abnormalities
within Age Categories in Males














Further investigation is necessary to make conclusio n about the age influence on the
incidence and prevalence rates of HPV-related cyto logic abnorma lities observe d in the study.
According to the evidence from the study conduct ed by Chin-Hong et al. HPV infection
by itself might be an independ ent risk factor for the subsequent developm ent of HIV infect ion
(Chin-Hong PV et ai, 2009) . Men infected with HPV serve as vec tors for the spread of the virus
to both men and women (Ferris DO, et ai, 2008). Higher HIV infection rates are seen among
patients already infected with HPV (Piketty C et ai, 2004). This assoc iation is believed to occur
through two different pathw ays. One way is that STIs such as HPV disrupt normal mucosal
anatomic barriers and may allow HIV-infected body fluids direct access to open and lor bleedin g
lesions.
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Another proposed way is that CD4+ T cells and macrophages are recruited in higher
numbers to skin surfaces infected with HPV, allowing closer potent ial contact between HIV-
infected fluids and host CD4+ T cells (Elam G et aI, 2008).
Men who have sex with men (MSM) have a high risk of deve loping ora l HPV infection.
A 2009 study conducted by D' Souza et al (Chin-Hong et al, 2009), found that ora l HPV
acquisi tion is more positively associa ted with the number of recent oral sex and open mouth
kissing partners than with the number of vaginal sex partners. Addit ionally, the prevalence of
ora l condylomas has increased dramatically since the introduction of Highly Active Anti-
Retroviral Therapy (HAA RT) (Rabkin CS, 1998; Bower M et ai, 2004; and Palefsky JM et al,
200 1), which may be due to immune reconstitution (BCCA Vancouver Centre). HPV not only
causes oral condylomas but is also strongly associat ed with oropharyngeal cancers and other ora l
diseases (Canadas MP et aI, 2004; Gillison ML et ai, 2008) . The incidence of HPV-associated
carcino mas of the oropharynx substantially increased from 1973 to 2004 (p<O.OO I) , most likely
because of a shift in sexua l behaviors, particu larly ora l sex in young males (Kreute r A &
Wieland U, 2009) . In our study we detected only one ASC-US cytologic change among all
oropharyngeal specime ns.
The conduc ted literature search and review discovered opposite opinio ns among
investigators regarding the impact of anti-HIV treatment on the incidence of HPV-associa ted
anal pre-cancero us lesions and cancer. Cranston RD et al in 2007 found that in contrast to most
AIDS-defining cancers, the incidence of HPV-associated anal cancer is increasi ng since the
advent of HAART (Cranston RD et al, 2007). The reasons underlying this trend are still
unknown and were not clarified by the investigators, but we can speculate that treatment of HIV-
positive men with HAART prolongs their life and subsequently prolongs the exposure of their
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anal canals to the high-risk HPV genotypes (Palefsky JM et ai, 200 1); Bower M et al in 2004 &
Palefsky JM et al in 200 1 showed that HAART decreased the rate of AIDS-related opportunistic
infections and neoplasia, even though anal cancer is not an AIDS-defining malignancy. This
evide nce was also confirmed by HIPVIRG study results. Most men in our study (mean (SO) age
was 47.20 (9.24)) have never been screened for anal abnormalit ies prior to the study. We
compa red our baseline data with the Canadian Human Immunodeficiency and Papilloma Virus
Research (HIPVIRG, 20 11) basel ine data except for the two last columns (OR and 95% CI) in
the Table below: their final results vs. our baseline results (Logis tic regression). The sample
size, median male age, percentage of smokers in the cohorts, percentage of patients who were
taking or about to initiate antiretroviral therapy, as well as their baseline C0 4 cell counts are
comparable between the cohorts. In our study we had a significantly less number of men with
undetectable viral blood level « than 50 copies/ml) at the enrolment into the study (8.7% vs.
54%).
SAMPLE MEDIAN VI.
STU DY SIZE AGE SMOKE RS IIAART CD4( Median) (undetectable) OR 95%CI
IIIPVIR G 247 43 y.o. 38% 90% 380cell s/mm' 54% 3.09 (40- 49 y.o.) 1.12 -8 .52
2002-2005 4.7850& > .0. 1.29 -1 7.73
112STU DY 275 45 y.o. 44% 90% 363c ells/mm' II.I % 0.76 (40- 49 y.o.) 0.17- 3.42
(2oo9 - 0 ngoing) 1.45 (50 & > y.o.) 0.41 -5 .10
The HIPVIR G investigators wanted to establish a comprehensive understanding of the
risk factors (age, smoking, initiation of anti-HIV treatment, C04 cell count, and viral load level)
for progression to AIN2 and 3. On entry to their study, 19% of patients had NILM (vs. 57.1% in
our study); 50% had LSIL (vs. 12.7%); AIN2 was present in 17%, and 13% of their males had
AIN3 (vs. 1% HSIL in our study). The cumulative incidence of AIN2 and 3 in their HIV-positive
male cohort was 23% after two years of observation and 37% after three years of observation .
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The follow-up result s from our study are required to analyze both the incidence rate o f
anal dysplasia and its correlati on with I-IAART and other underl ying risk factor s.
As has been seen in previously conduct ed studies (Kreuter A & Wieland U, 2009;
Palefsky 1M et ai, 2000), both the presence of HPV infection and the number of HPV genotypes
in the sample were important risk factors for pre-cancerous lesions. This study investigated the
association between cytologic abnormalities at multipl e sites (anal, oropharyngea l, and cervical)
and HPV genotypes detected at these sites for both genders separately. From 25 women in the
study, 10 had multip le HPV infect ions (2:3) in anal samples without local cyto logic
abnorma lities. The Table below demonstrated I-IPVgenotype distribution in the specimens from
four females with detec ted cytolog ic abnormalities:
Sample Site A nal Oral Cervical
ASC-US ASC-US ASC-US
54, 83 NEGAT IVE 51, 83
UNSAT NILM LSIL-HS IL
Cytology Report
& NEGATIVE NEGAT IVE 35,52
H PV Genotypes ASC-US NILM NILM
42, 51 NEGAT IVE NEGATIVE
NILM NILM LSIL
43, 67 NEGAT IVE 43
All 275 men in the study had only anal cyto logic abnorma lities and of these, 115 (42%)
had multipl e (3 or more) HPV genotypes . The result s demonstrated (Ta ble 14) a significant
asso ciation between multip le HPV types and anal lesions.
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TABL E 14
Association of Anal Lesions with the Number of HPV Genoty pes
in Male Population
Ana l Cyto logy 1 HPV 2 HPV ;:::3 HPV NILM P
Resul ts
ASCs 5 (12.2%) 5(12.2%) 28(68.3%) 3(7.3%) 0.002
LSIL 0(0.0%) 8(22.9%) 26(74.3%) 1 (2.9% ) < 0.001
HSI L 0( 0.0%) 1 (33.3% ) 2(66.7%) 0( 0.0%) 0.520
From this, it is plausible that infection with multiple HPV genotypes may be a marker of
persistent disease and of the progression of LSILs to HSILs (Palefsky JM, et aI, 1998).
Previous studies have demonstrated that behavioral determinant s were strongly
associa ted with the risk of ASILs (Fairley CK et aI, 1994; Burk RD, 1996; and Elam G et aI,
2008). Even patients who are knowledgeable about HPV and HIV can and do engage in high-risk
sexual behaviors (Chin-Hong PV et aI, 2004). Even though most HPV infections are transient,
MSM have more sexual partners, more new sexual partners, and therefore more new exposures
to HPV infection after age 30 years than most women (Burk RD, 1996; and Elam G et aI, 2008).
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The underlying behavioral risk factors that were included in this analysis: the number of
sex partners (both males and females) (Table 13A shows the association related to the number of
male partners in a last year), smoking status (Table IIA), and history of unprotected sex (Ta ble
12). There was no significance observed in the association of these paramet ers with the cytologic
abnormalities. There was no significant difference in the overall prevalence of ASILs by
geographic location also, where the highest peak of the prevalence reflects the highest number of
participants and consequently the highest number of abnormal cases in Halifax (Graph 2).
Graph 2













Finally, the association of cytologic abnormalities with baseline CD4 cell counts and
plasma viral load levels was analyzed. Two Canadian researchers Mougin C in 2001 and Leece P
in 2010 investigated the correlations between HIV infection laboratory markers (CD4<200
cells/ml and high level of plasma viral load) and incidence of anal dysplasia, and found a strong
relationship between these parameters. In this study no significance was observed between low
CD4 cell counts (T able 138 ) and the detected dysplasia in all types of specimen.
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All four viral load levels (Neve r Done; Undetectable; Detectable; Unknown) have been
analyzed in their assoc iation with cyto logic changes among the three types of specimen: Anal
with p = 0.493; Oral with p =0.998; and Cervica l with p =0.747. No significance was detected.
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Although no formal programs for anal cancer screening have been implemented in Canada or
elsewhere , guidelines on anal dysplasia screening have recently been developed by agencies in
the United States, by the United States Public Health Service, Centers for Disease Control and
Prevention , and the New York State Department of Health AIDS Institute. In 2004, the United
States Public Health Service mentioned anal screening in their guidelines for the prevention of
HIV-associated opportunistic infections among HIV-infected MSM (Adelstein OJ et ai, 2009).
The guideline states" .. .anal cytological screening of HIV-infected men who have sex with men
has not yet become standard of care but is now being done for high-risk persons in some health
care centres and may become a useful preventive measure in the near future." They also stated
that " .. .additional studies of screening and treatment programs for anal high-grade SILs need to
be carried out."
In March 2007, the New York State Department of Health AIDS Institute (Aberg JA et aI,
2004) updated its primary care approach for the HIV-infected patient and released guidelines ,
which recommended routine anal Pap testing (at baseline and annually) in several high-risk
groups. These were MSM, patients with a history of anogenital condylomas , and women with
abnormal cervical/vulvar histology. It was further recommended that patients with abnormal anal
Pap test findings be referred for high-resolution anoscopy and/or examination with biopsy.
One of the purposes of this study is initiation of an anal cancer screening program for the
populations at risk. The evidence from the Canadian HIPVIRG study strongly suggests
continuing research in this direction . The investigators believed that patients with a low nadir
CD4 cell count might especially benefit from screening for pre-cancerous lesions. In addition
"typing could also be useful as an adjunct to cytological examination in primary screening " (de
Pokomandy A et ai, 20 II) .
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5.2 Analysis of the Study Strengths and Limitatio ns
The Strengths of our study included: the large sample size (N=300), geographic diversity
(four Atlantic Provinces), and wide age spectrum of the participants (from 25 to 70 years of age).
There have been a number of Obstacles and Limitations to the study. The Obstacles to
overcome included:
• Meeting the requirement of a number of different ethics board
The application for the whole study approval was submitted to the ethics board in Ottawa
(HREA). Additionally, each study site (province) submitted the application to their local HREA.
The process was a time-consuming and delayed the beginning of the study.
• Inadequate and conflictin g literature related to obtaining specimens
Anal Pap smear screening involves the techniqu e of blind insertion of a swab into the anal
canal. The swab is inserted into the anus and vigorously rotated to scrape cells from the anal
lining. The collection device was then placed in SurePath media. This is different than the
majority of studies which have used ThinPrep for evaluation. Using the Liquid-based platform
results in better presentation of cellular material as multiple layers of cell material or obscuring
factors such as blood or inflammatory cells are removed. Samples taken from the anal canal have
the additional disadvantage of potential fecal contamination. During the initiation of the study we
received 50 unsatisfactory anal samples for evaluation. A literature search review with the
critical appraisal of the sources were conducted and widely discussed with the all research sites.
As a result of this process, it was decided to use NYS Guidelines recommendations on anal pap
smears for the anal sample collection (NYS Guidelin es).
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The Guidelines were distributed at all research sites in order to standardize collection in an
attempt to reduce the number of unsatisfactory specimens. Furthermore, based on the review of
evidence from different studies, it was decided to use Dacron swabs instead of the cotton ones
used initially (Lampinen TM et ai, 2006; Fox PA, 2006; Piketty C et ai, 2003; Chin-Hong et ai,
2005). Both these implementatio ns dramatically improved the quality of the collected anal
samples and reduced the number of unsatisfactory samples. It was also advised that co-
investigators recollect anal specimens from those who provided unsatisfactory samples at the
first time. Consequently, only 46 (15.3%) anal specimens remained unsatisfactory for
interpretation.
• Relocation of key study personnel
During the first year of the study there was no physician at the St. John ' s site and research relied
only on the help of physician ' s locum services. This significantly delayed the recruitment
process at this site.
• Size of the geographic region
• Varying degrees of buy-in from the study sites
• Small sample size for women (n=25)
Limitations are listed below:
• The major limitation was the study design; prospective cohort is an observa tional study
which is strong for correlations but weak for the investigation of the causative relationship
between risk factors and disease outcomes.
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• Another possible limitation of the study was the fact that only one pathologist read all of
the cyto logy results. Moreove r, any potent ial under- or overdiagnosis of ASILs would
probab ly affect only the prevalence estimates , not the estima tes of associa tions with the
potential risk factors. The study needs to follow all cases out to biopsy to confirm
cytologic interpretation.
• Finally, colposco py and HRA with biopsy as gold standards were applied to all
participants with abnormal cytology reports of varying degree but their results were not
analyzed at the time of this cross-sec tional study.
5.3 Conclusion
In this study, 74% (222) of patients had normal anal cytology, 26% (78) had abnormal anal
cytology. Abnormal cyto logy was reported mostly as ASCs (ASC-US (12.3%) and ASC-H
(1.0%)) ; LSILs (11.7%), with fewer samples showing HSILs (1.0%). That 26% of abnormal anal
specimens showed us the real burden of HPV-associated diseases and the need of screening
program implication for the population at the higher risk. According to the studies conducted by
Cranston ED et al in 2004 and in 2007, more than half of low-grade dysplasia in the cyto logica l
evaluation had high-grade dysp lasia on the biopsy . Anal cytology has a high sensitivity (95%)
for detection of dysplasia (ASIL) but a low spec ificity (50%) for predicting the severity of the
abnorma lity on subsequent biopsy. Even patients with cytologic diagnoses of ASC-US and LSIL
have significant risk (46% to 56%) of being diagnosed with HSIL (AIN 2, 3) at biopsy (Lytwyn
A et ai, 2005). These numbers suggest that all HIV-positive patients should undergo HRA
annually durin g their regular visit. All participants with the detected anal and cervical ASCs,
LSILs and HSILs were referred to the specia lists to undergo a high-resolut ion anoscopy (I-IRA).
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Previous studies have demonstrated that HPV type (i.e., high-risk versus low-risk) is
assoc iated with the type of lesions that develop later (Atkins 0 et al, 2004; Bosch FX et al,
2002).
In this study, 77.3% of the participants were HPV-positive, of these 42% had more than 3
HPV types. A total of 46 HPV genotypes were detected with HPV 16, 18, 45, 51 and 52 most
common at anus; HPV 16 and 52 at oropharynx; and HPV 16, 18, 35 and 52 most common at
cervix. The different distributi on of HPV types at different anatomic locations may sugges t the
further development of HPV vaccine against 35, 45, 51 and 52 genotypes. In this study, it was
also observed that infection with both high-risk and low-r isk HPV types was more strongly
assoc iated with LSILs or HSILs rather than infection with either high-risk or low-risk HPV types
only. This is consistent with the study observation that an increasing number of HPV types are
an important risk factor for ASILs. Given that earlier studies reported that only high-risk HPV
types are closely linked with the development of invas ive cervical and anal lesions, it was
concluded that the part icipants have been at risk for invasive lesions and will need to be followed
appropriately.
A cross-sec tional study was conducted to examine the temporal association between type-
specific HPV infection and progression of ASILs to invasive lesions and clarifies the assoc iation
between HPV infection with specific I-IPV types and the risk of l-ISILs. The compa rative analysis
of cytologic reports with histologic outcomes is required to draw conclusion about the real
prevalence of cytologic changes in participant s. The analysis of the follow-up years will also
allow us to conduct a comparative analysis in order to determine Incidence Rate (IR), Prevalence
Rate (PR) and Relative Risk (RR) in acquiring pre-cancerou s and cancerous lesions in I-1IV-
positive people in Atlantic Canada.
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Table 15
THE WHO HPV LABNET DATASET
HPV Assay Type Number of Datasets HPV Region Targeted (Primers)
All Assays 81 Ll/ElIE6/E7
I. Linear Array (Roche) 15 Ll (PGMY)
2.PGMY -RBH 7 Ll (PGMY)
3. In-house Type-Specific PCR 7 LlIE6/E7
4. In-house 16/18 Specific PCR 6 E6/E7
5. InnoLiPA (Innogenetics) 6 LI (SPFIO)
6. CLART (Genomica) 6 Ll (PGMY)
7. DNA Chip (Biocore) 4 Ll
8. In-house Lineblot 4 Ll (Gil)
9. In-house IlCR Luminex 4 Ll (GP or modified GP)
10. In-house PCR Luminex 4 E6/E7
II. In-house Microarray 3 LlIE7
12. PCR - RFLP 3 Ll
13. Microarray (Genetel) 2 LI
14. DEIA LiPA Assays 2 Ll (SPFI0)
15. In-house PCR E/A 2 LI
16. Microarray (Papillocheck) I EI
17. Type-specific PCR (GenolD) I Ll
IS. In-hou se I)CR Luminex I Ll (PGMY - Gil)
19. PCR Luminex (Multimetrix) I Ll (GP)
20. PCR E/A (GenolD) I Ll
21. In-house PCR Sequencing I LI (PGMY - G il)
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Table 16
CLINICAL MANA GEMENT GUIDELINES
(The 2001 Bethesda System)
RESULT RECOMMENDED MANAGEM ENT
Sneci menA de guacySta teme nt
Sat isfactory Routin e Scr eenin g at annu al intervals (unless the specimen adequacy statement is
acco mpan ied by aquali tierand subscqu ent recommenda tion).
Unsa tisfactory Rcpeat smeara fte r l2 weeks .
~
NIL Negative for Intraepithelial Lesion Routine screening*l f speciti cpathogen isp rcscnl, treat as d inieally approp riate.
*In the presenee of a gross abnormality with a negative Pap test, patient should bc referred forC olposeopy
Enit he lia lCellA bno r ma lit ies
ASC-US Atypical Squamous Ce lls of Women < 30 years of age: A repeat Pap test in six month s is recommend ed;
UndeterrninedS ignificance If ahnorrnal, refer for Colposcopy. If negative, repeat in six months. Aller two negative I'ap
tests, return to routine screening
Women > 30 years of age : \fP V Positi ve" Co lposco py a nd Biopsy
Women > 30 years of age: IH' V Negative " Rou t ine a nnua l scree ni ng
*HPVTesting will bc done through the laboratory automatically for ASCUS results in women over 30
years, A combined report will bci ssucd
ASC- \f Atypical Squamo us Cells canno t Co lposeopya ndBiopsy.
exd ude liS IL
LS IL Low Grade Squam ouslntraepith clial Co lposeo pyand Biopsy.
Lesion
IISIL lI igh Grade Squamous Intmepithclial Co lposcopy a nd Biopsy.
Lesion
AG C AEC - Atyp ical Endocervical Ce lls - Co lposco py and Endocervica l Curretage (ECC)
Atyp ical Gland ular Cell s For women ove r 35, endo metria l sampling is also recommended.
AEMC - Atypical Endo metria l Cells - Co lposco py and Endome tria l Samp ling (EM)
NOS - Not Otherwise Speci fied - Co lposco py, ECC and EM Sam pling
FN - Favor Neop lastic - Colposcopy, ECC and EM Sam pling.
AIS Adenocarcinomaln Situ Co lposeo py, Biopsyande ndoeerviea le urretage asreeommended.
Sq uamous Ce ll Carcinoma Co lposcopy a nd Biopsy.
Adeno carcinom a Colpos copy a nd Biopsy.
Othe r
Endometria l Cells in a woman over 40 (ora These findings should be interpreted in light of the clinical scenario. Clinicalc orrcla lionis
younger woman with unexplained vaginal advised. Endo met ria lbi opsyi srecomm endedifpost-me no l,a usa I or patient has abnorrnal




APPENDIX A: Study Ad Poster
HIV-HPV STUDY
Ifyou are HIV-positive male or female
& live in Atlantic Canada, we are
seeking your participation in an
Atlantic Canada HIV-HPV Study
For more information or to enrol in this study, please contact your
HIV clinic nurse or physician
Or, you may contact the study principal investigator:
Dr. Gerry Mugford
Associate Professor of Medicine and Psychiatry
Faculty of Medicine, Memorial University of Newfoundland, St. John's
Telephone: 709 777 7390
Fax: 709 777 7877
Email: gmugford@mun.ca; Pager: 709570-9090; Secretary: 709777-7346
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APPENDIX B: Consent Form
Faculty of Medicine . Schools of Nursing and Pharmacy of Memorial
University of Newfoundland; Eastern Health ; Dr. H. Bliss Murphy Cancer Centre
CONSENT TO TAKE PART IN RESEARCH
T IT L E
HPV genotype distribution in HIV-positive adults and HPV -related underlying risk facto rs
for oral, anal and genital malignancy: An Atlantic Canada prospective cohort study
SPONS O R
Public Health Agency o f Ca nada. Ottawa
CO-PR INC I PA L INVESTIGATORS
Dr. Gerry Mugford . Facult y of Medicine. Memorial University; Dr. Dan Fontain e. Faculty o f
Medi c ine. MUN; Dr. Sam Ratnam . Faculty ofM ed icine/Public Health Laboratory
CO- INVE ST IGA TORS
Drs . To m Wong and Gaya tri Jaya raman, Public Health Agency o I'Canada. Ottaw a; Dr. Alherto
Severi ni. National Microbio logy Laboratory. Winnipeg ; Drs. Gordon Dow and Bill Tho mpson.
The Moncton Hospital . Moncton; Dr. Duncan Webster . Atlantic Health Sciences Centre. Saint
Jo hn; Drs. Lynn Johns ton and Susan Kirkland . Faculty of Medicine. Dalhousie University. Halifax ;
Dr. Rod Wilson. South End Family Practice. Halifa x; Dr. Todd Hatchette , CDHA. Nova Scotia
Health. Halifax.
You have been invited to take part in a research study. It is up to you to decide whether to be
in the study or not. Before you decide. you need to understand what the study is for. what
r isks you might take and what benefits you might receive. This consent form explains the
study .
T he researchers will :
• d iscuss the stud y with you
• answe r your questions
• keep confidential any information which could identify you personally
• be available during the study to deal with problems and answer questions
If you decide not to take part or to leave the study. this will not affeetyour usual health care
a nd treatment.
I. Introduction/Background
Human Pap illomavirus (HPV) is the most common sexua lly transmitt ed virus. In most people. HPV
infection is temporary and doe s not lead to disease. There are many types o f HPV. Some types tend
to pers ist. and these types can cause oral . cervical, or anal cancer . These types may also cause
cancer o f the vulva. vag ina and penis. HPV is also the cause of genita l wart s. People with HIV or
with HIV positive partners are at a higher risk of cancer and genital warts . A number of stud ies say
these people should be tested tor HPV-related diseases. As the risk of HPV related cancers is higher
with some types of HPV. knowing the types may help care for patients. Also. there is little known
about which types of HPV are more common in HIV positive Canadians . This information is useful
for public health HPV surve illance and vaccination programs, Therefore, we are doing this study to
lind out: the types o fHP V are found in persons living with HIV in Atlantic Canada. underlying 72
diseaseo r diseasc outcome,and the associated riskfactors.T his study will hclp us better unders tand
HIV-HPV co-infection .
2. Purpose o f Study
This study will assess what types o f HPV are found in persons living with HIV in Atlantic Canada.
We will also look at the risk o f HPV associated cancers and genita l warts and the underl ying risk
factors.
3. Description of Study Proccduresand Tests
You will be asked to till out a confidential que stionnaire . The questi onnair e will ask about your risk
factors and behaviour . Someofthequestions are general, and others arc more personal about your
sex life. We askthesetypesofqu est ionsbeeausewearetryingtotindbehavioursthat might
increase your risk ofHPV related disease s. You will only have to complete the quest ionna ire once.
You can freely refuse to answer any o f the questions .
Yo u will be asked by the clinic nurse or doctor to give an anal speeimen and throat specimen, and if
you are female you will be asked to give a cervical specimen as well, for Pap and HPV tests. Your
doc tor will receive the result s and this may be useful in your care and treatment. You will be asked
to provide the specimens once a year tor 3 more years. This is to see if you have or develop ed any
HPV related disease. We also ask your permission to get informati on from your medical lile. This
is to get informat ion such as your HIV viral load and treatment s, etc. We usc this informati on to see
ifit re lates to any HPV related disease you might have or develop .
4. Lengt h of T ime
This study will take place during your regular clinic visits. It will take about 20 minutes to complete
the quest ionn aire once at enro lment. The specimens will be collected oncc a year for 3 more years .
5. Possib le Risks and Discomforts
There are usuall y no serious risks associated with taking an oral, anal or cervical specimen.
Some people feci discomfort when specimens are taken. Some people may find giving specimens
embarrass ing. The specimens will be taken in a standard way and the nurse or physician will try to
minimize any discomfort .
There are usually no risks associated with complet ing the questionnaire. Some people may
experience discomfort tilling in questionnaires . The stress is usually mild.
6. Benefits
The information from your annual oral. anal and/or cervica l Pap smear will be useful in your ca re
and treatment. Knowing the HPV types may also be useful. Howe ver, it is not certain this study will
benefit you.
7. Liability statement
Signing this form gives us your consent to be in this study. It tells us that you understand the
informat ion about the research study. When you sign this form, you do not give up your legal
rights. Researchers or agencies involved in this research study still have their legal and professional
responsibilities.
8. Confident ia lity
Your participat ion in this stud y and all information about you will betreated as contident ial. Only
people involved in this study or part of your health care team will have aceess to your records. The
que stionn aire will be completed in your privacy and placed in a sealed envelope and given to the
cl inic nurse. This will be sent to the principal investigators. Throughout this study. your
ident ificat ion will be retained so that we can link Pap and HPV results to sec if you have any risk
tor HPV related diseases. Your name will not appear in any o f the study report s. All informati on 73
will he held in encrypted computer databases and protected by passwords . All records will be kept
in a locked storage and will remain confidential. The research records will be kept for 10years and
your specimens lor up tolO years after the completion of the study. A fterthis,thercsearchrecords
and your specimens will he destroyed and not used for any future researc hstudies.
9. Questions
If you have any questions about taking part in this study, you can meet withthe investigator who is
in charge of the study at this institution . That person is: Dr. Gerry Mugford, 7097777390
Or you can talk to someone who is not involved with the study at all, but can advise you on your
rights as a participant ina research study . This person can be reached through:
Office of the Human Investigation Committee IHIC) at 7097776974
Email: hicr,l ll1!l!ill
Hcalth Canada Rc-;carch Ethics BoarJ at (113 941 5199 (Cllllcct call acceptcd l
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Signature Page
Study Title: HPV genotype distribution in HIV-positive adults and HPV-rclated underlying risk
factors for oral, anal and genital malignancy: An Atlantic Canada prospective cohort study
Investigators. Drs. Gerry Mugford, Dan Fontaine and Sam Ratnam
To be filled out and signed by the participant
I have read the consent [and information sheet] ,
I have had the opportunity to ask questions/to discuss this study .
I have received satisfactory answers to all of my questions.
I have received enough information about the study.
I have spoken to Dr. _ _ and he/she has answered my questions
lunderstandthatlam free to withdraw from the study
• at anytime
• without having to give a reason
• without affecting my future care [student status, etc .]
Please check as appropriate:
Yes { } No {}
Yes { } No {}
Yes I} No {}
Yes { } No {}
Yes I } No t}
Yes { } No {}
I understand that it is my choice to be in the study and that Imaynotbcnelit. Yes {} No {}
I agree that the study doctor or investigator may read the parts of my hospital Ycs l } No I}
records which are relevant to the study .
Future use of tissue/DNA samples (if applicable):
In order to preserve a valuable resource, your specimens will be sto red at the end of this research
project. It is possible that these samples may be used in future researchprojects.Anysuchstudies
will be carried out as determined by a research ethics committee. Any future research would have
to be approved by a Research Ethics Board (REB).
Please tick one of the following options:
I agree that my specimens can be used forapprovcd research studies without contacting
me again, but only if my name and other personal information cannot be Iinked,inany
way.jo the specimens.
Under no circumstances may my specimens be used for future research. My specimens
must be destroved at the end of'the present researchstudv.
I agree that I may be contacted in future to be invited to provide consent for the use of
m specimens in an new approved research studies.
If you have agreed that your specimens can be used for future research. they will be stored at the
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, tor an
undetermined period of time . Your name, Mep number, address etc, cannot be linked to the
specimen. If you have indicated that your specimens cannot be used for future rcscarchthey will be
destroyed at the end ofthisstudy.
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I agree to take part in this study
Signature of participant
Signature of witness
To be signed by the Study Nurse/Doctor
Date
Date
Yes {I No {}
I have explained this study to the best of my abi lity. I invited questions and gave answer s. I belie ve
that the partieipant fully understands what is involved in being inthestudy,anypotentialrisksof
the study, and that he or she has freely chosen to be in the study.
Signature of investigator Date
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APPENDIX C: Patient's Questionnaire
Today's Date : I I
YYYVMMDO
Encryptcd Participant lD : _
H2STUDV
Pati ent Qu estionnaire
rOil can help liS better understa nd the relationship between liP V and II I I' by answering a few questions
These questio ns are completely confidential. 1'0 11may refu se 10 answer any or all of these questions. Your
medimlcare\l'illnolbeuj{i:ctedinuIIY II'uY!/)'o llc hoosellotto take panilllhisstl/l(v.7hu nkyou(;'ryour
Firs t arc some general questions about your background:
I I
YYYYMM DO
3. If yo u we re no t born in Ca nada, in what yea r did
you come to Canada to live'! _ (YYYY)
5. What is your ethnic /cu ltural background? (chec k
all that apply)
o Aboriginal :
o First Nat ions
o Metis
o Inuit





6. What is the highest level of schoo ling you
completed?
o None
o Eleme ntary school
o Some high schoo l. bu t no diploma
Dllighschooldiploma
D Som" collegcluniversity
D College!univers ity diploma or degr""
o Graduate Deg ree
2. lnwhalcountrywereyou born'!




o Latin Ame rican (ex : Cen tra l or Sout h America n)
O S lackA!iican
o Sl ack Carib bean
o So uth Asian (ex: Indian. Pakistan i. Bangladeshi.
Sri Lankan)
o South-East Asian (ex : Indonesian, Tha i.
Cambodian. Malay)
o White (Caucasian)
o Other . please spec ify _
Next arc some qu estions about your medical history , health and sexualprac tices:
7. Do yo u smoke ciga rettes'!
o Yes. daily
o Yes. occasionally
o I used to smo ke. but quit
o No. I have never smo ked ciga rettes
SArc you mele or fcmalc?
o Male i/Of./LE.pleascgo loq lleslionJ.lJ
o Female
o Other. specify: _
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I':ncry pted Participant lD : _




o 3 or more
II . Have you ever had a cervica l Pap test before
today'? (ljNO. go to question 13)
D Yes
D :--.ro
D Oon' t know
13. Have you had cancer of the cervix')
D Yes
D ~o
D Onn' t knnw
IS. Have you received the new HPV vaccine?
D Yes
D No
D Onn' t know
17. During the last year, how many sexua l partners
have you had?
__ male partners __female partners











12. When was your last cervical Pap test before
today?
o LL'SS than 6 months ago
o 6 months 10 less than 1 year ago
D lycar loless than3yearsago
0 3 years to less than S years ago
o S or more years ago
D Oon'l know




16. Have you ever had oral.unal.u r vaginal sex or
othe r genital-to-genital contac t?
D Yes
D Nn
D Oon' t know




D Oon' t know






Toduv's Date: I I
. fflVmIDD
EncryptcdParticipantlD: _




Chlamydia 0 D 0
Gonorrhea 0 0 0
Syphilis DOD
Genital D D 0
herpes
Ot her (ple ase specify)










Please answer, to the best of your knowledge, whether you think the following three statements are
true or false:
n . HPV docs not cause anogenital warts
D True
DFalse
D Don' t know
14. There is a vaccine that can lower risk lor
anoge nitalwarts and ahnorrnal Pap tests
D True
D False




The next two questions askyour~aboutPap testing, safer sex practices, and IIPV
vaccination:
25. In your opinion, how important is it tor
women who have the IIPV vaccine to have regular





D Not at all important
DNots ure
16. Invouropinion, how import ant is it for those
who have the HPV vaccine to continue to pract ise
safer sex'?
o Extrem ely important
D Veryi mportant
D Somewh at import ant




APPENDIX D: l Z-item Clinical Questionnaire
112 STU DY
12-lte m BaselineClinicQuestio nnaire
To be completed by Physician / Nurse
PatientlD: _
1. Specimens collected
Date of collecti on
3. Hastheparticipantrcceivl.-dHPV vaecination '?
Ify es:
a. Date ofl "HPVvaccinedose
b. Date of 2""HPVvaccinedose
c. Dateo OnlHPV vaccincdose
4. Date of first positive HIV test
5. BaselineCD4+ count and date (use the
closest date to the first positive HIV test date)
6. BaselineH IVplas maviral loadanddate(use
























D Undetectable at <50 copil.-slml
I I
YYYY MMOO-
D Detectable at __ copies/m l
I I
YYYY MM 00-
D Never had viral load tcst 80
7. Evcr on anti -Hlv medicat ion?
8. Currcntly(i.e.,atthetimeofcntryinto
the current study) on anti-HIV medication?
9. Current AIDS-detining criteria I event
10. rreviousA IDS-definingc riteria /event
II . Any previous histology I clinical data relative to
oral,ccrvical,anal,genitalpre-ca ncer lesions,
warts etc.






D Don' t know
DYes(ifyes,pleasedescribebelow)
D None
D Don' t know
D Yes(ifyes,p leasedescribe below)
DNone
D Don' tkno w
D Ycs (if ycs, please deseribe below)
D No
DDon'tknow
D Ycs (if ycs, provide info below)
D No





APPENDIX E: Patient's Enrolment Card
9 . T d cpl lllnc H: _
1 7.1 ~IFoliowupUue()atc :~
3 1. 2Utl FolluW lIp D lle J)Jl te: _
45. J"' Follow Ull OUe U,tle: _
54. Speci men Col lected
.16. Compliant






APPENDIX F: Specimen Collection Guidelines
Technique: (NYS Guidelines recommendations on anal pap smears, NYS DOH AIDS Institute's
HIV quality-related website - http://hivguidclines.org/Content.aspx ).
There is no preparation necessary before obtaining anal cyto logy. If the digita l recta l
exam ination is performed in conjunction with anal cytology and/or HRA, the cytology must be
obtained first, before lubrication is introduced into the anal canal. Patients should not have
received an enema or engaged in receptive anal sex within 24 hours before sampli ng because
these activities can adverse ly affect specimen quality.
The standard technique used in obtaining anal cytology is as follows: a Dacron swab (a
cotton swab will not yield accurate results) is moistened with sterile or non-sterile water. The
anus is spread with the index and thumb of the non-dominant hand so that the anoderm pouts out.
The swab is then gently inserted into the anal canal as far as it will go, until it hits the wall of the
rectum . If the swab does not go in easi ly, the angle of insertion should be adjusted. The presence
of externa l hemorrhoids may cause resistance ; in this case, different insertio n points should be
tried until the anal canal is easily accessed. The swab must be inserted above the
squamoco lumnar transition zone, which is approximately 2 ern (1 inch) from the anal verge .
The swab is then slowly moved in and out without comp letely withdrawi ng it, while rotating
it in a spiral motion and applying mild pressure to the anal wall. Afte r severa l rotations , the swab
should be withdrawn and immediately immersed in methanol-based preservat ive-transport
solution . Feces or traces of blood on the swab will not affect the result. The swab should be
agitated in the solution for 60 seconds to transfer cells from the swab to the medium.
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G enotyping
APPENDIX G: Flow Chart (screening year)
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